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ABSTRACT
The nature of the iinrnunoreactivity of hepatitis B surface 
antigen (HBsAg) has been examined by mutation of specific amino acid 
residues. The replacement of arginine at 122 for lysine, or 
replacement of tyrosine at 134 for phenylalanine, when combined with 
the substitution at 113 (serine -*  three-nine) switched the antigenic 
subtype of HBsAg from y+d" to y+d+ . However, differences in 
antigenic subtype were, not attributable to any single amino acid 
substitution. The effect of these mutations (most notably at 122) on 
the subtype of anti-HBsAg sera was more dramatic, a combination of 
all three mutations facilitated the complete switch of immunogenic 
subtype from y to d. Proline 142 was required for the exhibition of 
full antigenicity of the iiraminodominant a-region. Replacement of 
cysteines 124 and 147 by serines drastically reduced or eliminated 
antigenicity, which implicates these two residues in stabilising the 
conformation of the antigen. The a-region of HBsAg has also been 
shown to influence both the immunoreactivity of the adjacent subtype 
antigenic region, despite being immunologically distinct from it, and 
the ability of the antigen to interact with a subtype-specific 
monoclonal antibody. These results emphasise the importance of the 
polypeptide region between the cysteine residues 124 and 147 in 
determining a-antigenicity as well as manifestation of the subtype of 
HBsAg.
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rpm revolutions per minute
SDS sodium dodecyl sulphate
SSC standard saline citrate
TCA Trichloroacetic acid
Tm melting temperature
Tris.HCl tris (hydroxymethyl) aminomethane
	hydrochloride
Triton X-100 octylphenolpoly (ethyleneglycolethan)
TTP thymidine triphosphate
XP X gene promoter
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The association of a viral particle with the disease state of 
hepatitis B was made by Blumberg in 1967, when the so-called 
Australia antigen (HBsAg) (Blumberg, 1965) was implicated with acute 
hepatitis B in a number of patients. Since the discovery of the 
viral pathogen responsible for the human liver disease of hepatitis B 
analogous agents have been discovered to cause similar conditions in 
the woodchuck (Summers et al., 1978), the beechy ground squirrel 
(Marion et al.. 1980) and the Pekin duck (Mason et al.. 1980) . Along 
with the Hepatitis B virus (HBV) of humans these animal viruses 
comprise the Hepadna group of viruses, their taxonomy being based on 
similarities in viral particle structure, genome organisation, and 
disease characteristics.
1.2 Biology of Hepatitis B Virus 
1.2.1 Hepatitis B virus particles
The HBV virion, known as the Dane particle, appears in infected sera 
as a spherical 42nm diameter particle (Dane et al., 1970). It has an 
inner core of 27nm (containing virus genome and associated core 
antigen), and an outer envelope of 7nm thickness containing the 
surface antigen (HBsAg) (Cossart, 1971; figure 1.2.1). This complex 
glycosylated lipoprotein is also present in the serum of infected
Figure 1.2.1 Structure of the HBV virion (from Murray, 1987)
The Dane particle (42nm in diameter) is composed of an outer 
envelope and a nucleocapsid core (27nm in diameter). HBsAg is 
located in the outer envelope along with lipid; present in the 
serum of infected individuals are spherical particles composed of 
HBsAg of diameter 22nm and filaments of similar diameter. The 
nucleocapsid is composed of the core antigen (HBcAg) and the 
partially double stranded CNA genome of the virus. Also associated 
with the core particle are the X antigen (HBxAg), the e antigen 
(HBeAg) and a DNA polymerase activity.
Figure 1.2.3 Immunological profiles of hepatitis B disease states
(from Murray, 1987)
The temporal progression of acute and chronic hepatitis B indicated 





















HBcAg: one polypeptide, MT 21 000
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individuals as spherical particles with a diameter of 22nm or 
filaments of similar diameter. HBsAg exists mainly as a 24kD (p24) 
or 27kD (gp27) glycosylated derivative in 22nm particles and Dane 
particles (Peterson et al.. 1977). There are however larger less 
abundant forms, namely the 33kD glycoprotein, gp33, and the 36kD 
glycoprotein, gp36, present in 22nm particles and Dane particles, as 
well as other larger forms such as gp42 and p39, and minor, very high 
molecular weight polypeptides (Heermann et al.. 1984). The inner 
nucleocapsid contains the core antigen (HBcAg), which is composed of 
a major polypeptide of molecular weight approximately 23kD. Also 
found in infected sera is the e antigen (HBeAg), which is a soluble 
component of the nucleocapsid and can be produced in vitro by 
proteolytic cleavage of HBcAg when dissociated (MacKay et al., 
198la). The nucleocapsid contains the virus CNA, a DNA polymerase 
activity (Kaplan et al.. 1973; Robinson and Greenman, 1974) and a 
protein kinase which can phosphorylate the major core protein. On 
the basis of amino acid sequence deduced from the nucleotide 
sequence of its gene, HBcAg has a protamine-like C-terminus and since 
it is located in the nucleocapsid is likely to be a DNA binding 
protein.
The HBV genome has a characteristic and unusual partially double 
stranded form (for a review see Robinson, 1977) (figure 1.2.2). The 
single stranded portion varies in length from approximately 15 - 50% 
of the complete strand with a preferred minimum length of 650 - 700 
nucleotides. The short strand has a variable 3' and fixed 5' 
position relative to the long strand. The long strand is 3.2kb long
Figure 1.2.2 HBV genome structure and transcriptional signals
(drawn by R Jackson)
Open reading frames (in three translational phases) are indicated by 
heavy lines. Promoter and enhancer sequences are denoted by 
rectangular boxes. The numbering system is based on position 1 being 


















































































































































































































































































































































and has a nick located at a unique site which is situated 
approximately 200 nucleotides from the 5 1 end of the short strand, 
where a protein of unknown function is covalently attached (Gerlich 
and Robinson, 1980).
1.2.2 Clinical aspects of hepatitis B
Hepatitis B is a worldwide public health problem of immense 
importance, with some 2 x 108 carriers of the virus in the world. 
The HBV virus can be transmitted by saliva, semen and blood in a 
horizontal or vertical fashion and exerts it pathogenic effects in 
humans and chimpanzees by infection of the liver with concomitant 
hepatocyte damage. A particular feature of HBV, and of all hepadna 
viruses, is that infection exhibits great tissue and host specificity 
occurring only in the liver of humans and chimpanzees. Infection may 
result in the acute form of the disease or develop into longer-lived 
chronic hepatitis B. The latter form can give rise to substantial 
liver cirrhosis and is believed to represent 5 - 10% of all HBV 
infections; chronic infection may also lead to a carrier state 
characterised by the persistence of viral antigens in the patient's 
serum in the absence of other pathological features. This may 
ultimately lead to viral DMA integration into the host chromosome and 
even to the development of hepatocellular carcinoma or primary liver 
cancer (Vyas et al.. 1978; Szmuness et al., 1982).
The serological profiles of acute and chronic disease states are 
represented in figure 1.2.3. The initial component detectable in
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serum is HBsAg, which is usually produced in large amounts, followed 
by HBeAg; the other nucleocapsid antigen HBcAg is not normally 
detected in infected sera. Both of the serum antigens appear just 
before the onset of detectable hepatocyte necrosis, manifested by 
serum transaminase activity, and patient jaundice. However, 
antibodies to viral components including those against HBcAg appear 
at the same time as the manifestation of tissue damage. If the 
individual develops the chronic form both HBsAg and HBeAg may 
persist in sera, furthermore upon integration of HBV DMA HBsAg may be 
produced by active transcription of integrated viral genes long after 
the disappearance of Dane particles from the serum.
Vaccines against HBV have been developed from HBsAg, either purified 
from infected sera in the 22nm particle form (for review Maupas and 
Guesry, 1981; Szmuness et al., 1982) or produced by recombinant DMA 
methods (Murray et al.. 1984). The vaccine based on serum derived 
HBsAg has been proven safe and effective and is used widely (Szmuness 
et al., 1980). Due to the problems associated with the high cost of 
the serum derived vaccine plus the necessary purification and testing 
procedures, and fear of HIV contamination, the rationale for 
producing HBsAg by expression of the gene in microbial systems (S_._ 
cerevisiae) by genetic engineering was born. The antigen produced 
behaves immunologically similarly to the native protein and also 
forms 22nm-like particles on expression in yeast (Murray et al., 
1984; Miyanohara et al., 1983; Valenzuela et al., 1982; Hitzeman 
et al., 1983). The recombinant protein also protects chimpanzees 
challenged with HBV, and has now been approved for general use. By
using HBsAg as a vaccine we assume that prophylaxis is afforded 
through priming of the immune system by the antigen, before viral 
challenge. Recent work has revealed the importance of pre S protein 
domains in facilitating virus uptake into hepatocytes (Neurath et 
al., 1986b). Therefore a new generation of candidate pre S/S antigen 
vaccines is being produced by genetic engineering techniques 
(Valenzuela et al.. 1985a, b).
1.2.3 HBV genome organisation
The complete nucleotide sequence of the HBV genome was established 
following its cloning in Escherichia coli (Pasek et al., 1979; 
Galibert et al.. 1979) (Appendix A). It shows that the organisation 
of genetic information is compact, with the presence of 4 open 
reading frames in all 3 translational phases of the 3.2kb long 
strand (minus strand) and one small potential gene (700HBV) in the 
short strand (positive strand). The predicted locations of the genes 
for HBV components in terms of the 4 open reading frames (ORF) were 
established by cloning, sequencing and expressing restriction 
fragments of the genome in E. coli and comparing nucleotide sequence 
and expression product with the native HBV protein (figure 1.2.2).
HBsAg: The HBsAg gene was mapped to nucleotide positions 1437 - 2114 
by comparing the predicted amino acid sequence of the ORF with the 
partial amino acid sequence of serum derived HBsAg (Peterson et al., 
1977). The S gene gives rise to the p24 protein and its glycosylated 
form gp27 (Peterson et al., 1977; Peterson, 1981; Skelly et al.,
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1978). The larger forms, gp33 and gp36, represent S gene and pre S2 
translation products, the largest forms,present in consistently small 
amounts, are the p39 and gp42 proteins which represent pre Sl-pre 32- 
S gene translation products. The coding basis of these forms of 
HBsAg protein was deduced using monoclonal antibody probes, specific 
for synthetic peptides representing the different domains, to detect 
the presence of these regions in the various forms of the protein 
(Heermann et al., 1984). Other evidence implicating the pre S region 
in HBsAg proteins derives from the observation that secretion of gp33 
and gp36 from HBV CNA transfected, L-cells is abolished by altering 
the reading frame of the HBV ENA 10 nucleotides downstream of the pre 
S2 ATG, whereas p24 and gp27 secretion is unaffected (Persing et al.. 
1985).
HBcAg: The core gene was mapped to nucleotide positions 1 - 549 by 
expression of the antigen in E. coli followed by immunological 
characterisation of the recombinant protein (Pasek et al.. 1979) and 
electromicroscopic characterisation of the core particles produced 
(Cohen and Richmond, 1982).
Ninety nucleotides upstream of the HBcAg gene start there is an in- 
phase initiation codon. The region between the 2 initiation points, 
denoted the pre-core region, encodes largely hydrophobic residues and 
is conserved between all the members of the Hepdna viruses (Moroy et 
al., 1985; Enders et al., 1985). HBeAg represents a proteolytic 
cleavage product of HBcAg (MacKay et al., 1984a), with the loss of 
between 34 and 36 amino acids from the C-terminus of core during e-
11
antigen biosynthesis (Takahashi et al., 1983). It has been shown 
that the pre-core sequence is necessary for HBeAg production and 
secretion but not for HBcAg (McLachlan et al.. 1987; Roosinicck et 
al., 1986; Ou et al.. 1986; Vy et al.. 1986). The mRNA utilised is 
the low abundance core promoter transcript initiating 5 1 to pre-core 
giving rise to pre-core/core messages (McLachlan et al.. 1987). The 
processing of pre-core/core protein into secretable HBeAg involves 
the endoplasmic reticulum (ER) association of nascent protein via the 
pre-core signal sequence (Schlicht et al., 1987; Vy et al.. 1986; 
Ou et al., 1986) and subsequent cleavage of signal when it enters the 
lumen of the ER. The C-terminal cleavage of core is also membrane 
associated allowing its conversion to HBeAg and secretion (Schlicht 
et al., 1987). Based on protein sequence homology it is argued that 
the N-terminus of core contains a protease domain, and that this 
protease catalyses the self cleavage of membrane associated core 
protein into HBeAg (Miller, 1987). As well as C-terminus removal the 
other post-translational modifications carried out on core by the 
secretory mechanisms of infected cells are membrane associated 
phosphorylation (Roossinick and Siddiqui, 1987) and glycosylation 
(Schlicht et al., 1987). The cryptic protease activity of core is 
activated, it is suggested, by post-translational modifications 
inferring that activity is dependent on the glycosylation and/or 
phosphorylation of membrane associated core then allowing full e- 
antigen conversion (Miller, 1987). Consideration of membrane 
associated core peptides as viral proteases has allowed the 
postulation of a retroviral like scheme for the maturation of core 
and polymerase gene products by proteolysis of core-pol polyproteins
12
produced from the translation of genomic length HBV messages. Such 
fusion proteins have been detected in cell culture systems (Junker et 
al., 1987) and primary liver carcinomas (Will et al., 1986), and are 
thought to be analogous to the gag-pol fusions found in retrovirally 
infected cells which are resolved by self cleavage by the protease 
region of gag (Ganem and Varmus, 1987).
Several investigators claim that as well as pre-core allowing HBeAg 
production, the signal also targets HBcAg destined for nucleocapsid 
formation to the ER, so facilitating core-envelope interactions in 
the assembling virus (Ou et al., 1986; Vy et al.. 1986). However, 
in the light of the finding that mutations in the pre-core of DHBV 
abolishes HBeAg secretion in a Hep-G2 cell culture system but not 
virus assembly, it seems that pre-core is not needed for nucleocapsid 
formation (Schlicht et al., 1987). This result is supported by the 
observation that similarly mutated DHBV is still infective when 
injected intrahepatically into new born ducks, whereas HBeAg 
secretion is diminished (Chang et al., 1987). It seems therefore 
that nucleocapsid formation and association with HBsAg derived 
envelope does not require the secretory pathway, but that cores form 
spontaneously as they do when produced in E. coli (Stahl et al., 
1982; Cohen and Richmond, 1982) or other expression systems (Murray, 
1987).
HBxAg: The other putative gene present in the pre-core/core 
translational phase is the so-called X ORF (Tiollais et al.. 1981), 
which was not until recently assigned a protein coding function. It
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had been shown that a mRNA species of the size expected for the X 
message existed in a rat cell line transformed with HBV DNA, rat 
2/130.4/TK4 (Gou^i, 1983). The X ORF has now been expressed in E.. 
coli (Puqh et al.. 1986; Meyers et al., 1986; Kay et al.. 1985) and 
a protein of expected size and amino acid sequence produced. The 
recombinant protein identified X specific antibodies in HBV infected 
sera and produced antibodies which reacted against HBV DNA 
transfected cell lines (Pugh et al.. 1986; Meyers et al.. 1986; Kay 
et al., 1985). Furthermore, X specific synthetic peptides gave rise 
to antisera which detected HBxAg in HBV infected liver and 
hepatocellular carcinomas (Moriarty et al.. 1985). There is evidence 
to support the view that X protein functions as a transcriptional 
activator via a trans mechanism (Twu and Schloemer, 1987; Spandau 
and Lee, 1988). X protein can apparently trans-activate other viral 
enhancers and the X ORF has been shown necessary for S gene 
expression from the SPII promotor in a transient cell line assay 
system (R Jackson, personal communication).
pol ORF: The large open reading frame occupying 80% of a single 
translational phase is thought to code for the DNA polymerase/ 
reverse transcriptase enzyme associated with Dane particles (Kaplan 
et al.. 1973). The indirect evidence for this proposal is based on 
the fact that the ORF has the capacity to code for a protein of size 
93kD, comparable with the size of other enzymes of similar function 
and that the predicted amino acid sequence bears similarities to the 
other reverse transcriptases (Ton et al.. 1983). The possibility 
that the polymerase activity associated with Dane particles is due to
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a host cell mammalian DNA polymerase encapsulated by the virion seems 
slight, since the HBV activity has different ionic requirements to 
that of mammalian DNA polymerases (Hess et al.. 1981). Direct 
evidence for the pol ORF encoding such a protein comes from the 
expression of the protein in E. coli in the form of a /3-galactosidase 
fusion. The recombinant protein was found to have reverse 
transcriptase activity and anti-sera raised against it cross reacted 
with sera from HBV infected chimpanzees (McGlynn and Murray, 1988).
1.2.4 Transcription of the HBV genome
Until recently the study of gene expression of HBV during its normal 
life cycle has been made difficult by the lack of a laboratory host 
or cell culture system. However, now several groups have succeeded 
in propagating the virus in cell culture by the transfection of Hep- 
02 hepatoma cells with cloned HBV DNA (Sureau et al., 1986; Yaginuma 
et al.. 1987). Before this system was available other approaches 
were used including the study of transcription of the genes of other 
Hepadna viruses after host infection, and HBV transcripts from 
infected chimpanzee livers. The establishment of cell lines 
expressing some HBV genes, by transfection with cloned HBV DNA in a 
mammalian virus expression vector or co-tranfection with a selectable 
marker and the use of hepatomas such as PLC/PRF/5 (Alexander et al.. 
1976) bearing integrated HBV sequences, has led to progress in the 
study of HBV gene expression. Using vector mediated transfected cell 
lines (Moriarty et al.. 1981; Christman et al.. 1982) and the 
PLC/PRF/5 system (Cnakrabarty et_al., 1980; Edman et al. . 1980) the
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S gene mRNA was identified as a 2.1 - 2.5kb species by hybridisation 
of total mRNA to radioactively labelled genome segments. An HBV DNA 
transformed mouse cell line was made by co-transfection with the 
Herpes Simplex Thymidine Kinase gene (TK) into TK~ recipient cells. 
The HBV CNA became integrated but the only viral gene expressed was 
that of HBsAg as a 2.1 - 2.5kb message (Dubois et al.. 1980; 
Pourcel et al.. 1982). A more useful system was created by co- 
transfection of TK~ rat 2 cells by cloned HBV DNA present as four 
tandemly arranged copies of the genome and TK to produce rat 
2/130.4/TK4 (Gough and Murray, 1982). In this system HBsAg, HBeAg 
and HBxAg (Pugh et al., 1986) were detected; also by Northern blot 
analysis of total rat 2/130.4/TK4 mRNA four distinct HBV specific 
mRNAs were identified (Gough, 1983). The most abundant species was 
the previously detected HBsAg message, there were also two greater 
than genome length messages of approximate sizes 4.2 and 4.5kb, the 
fourth message was a transcript hybridising to the X region of the 
genome.
The area of sequence necessary for S gene transcription was initially 
defined by transfection of Ir-cells with DNA fragments from which 
deletions had been made upstream of S (Pourcel, 1982) and by mapping 
of the S transcript by hybridisation with a range of labelled genome 
fragments with total message (Gough, 1983). Between the two 
approaches the region 523 - 900 was identified as necessary for S 
transcription and a putative promoter, TATATAA identified at 876. 
This TATA-like promoter has also been identified by in vitro 
transcription studies (Rail et al., 1983). The initiation point of S
16
gene transcription was further mapped by SI nuclease digestion and 
primer extension experiments on S message from HBV infected 
chimpanzee livers and rat 2 cells transformed with HBV DNA showed 
that transcription started at position 1256, 185 nucleotides upstream 
of the start of S and in the pre SI gene (Cattaneo et al., 1983, 
1984). The proposed promoter sequence at 1215 is atypical of the 
TATA-like RNA polymerase II promoters, but is similar to the SV40 
late promoter (Brady et al.. 1982), sharing the common GAAGGNA- 
OCTANCC sequence; also in vitro transcription studies identify the 
1215 rather than the 876 sequence as the S promoter (Standring et 
al., 1983).
These findings are difficult to rationalise in the light of earlier 
work establishing the TATA-like sequence at 876 as the S gene 
promoter. Quantitation of transcription from SP1 (876) and SPII 
(1215) promoters by assaying the levels of Chloramphenicol Acetyl 
Transferase (CAT) activity from hybrids of SPI or SPII and the 
bacterial enzyme gene (Siddiqui et al. . 1986) has revealed that 
approximately 98% of transcription occurs from SPII and 2% from SPI. 
Thus, S transcripts of varying lengths (2.1 - 2.5kb) are transcribed 
from the dominant SPII and weaker SPI promoters with only SPI 
transcripts coding for gp42, and p39 forms of HBsAg - the abundance 
of SPII derived transcripts is consistent with the fact that p24, 
gp27, gp36 and gp33 are the major forms of HBsAg in Dane and 22nm 
particles (Heermann et al.. 1984).
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The HBV genome contains a single polyadenylation site TATAAA at 
position 16 where all transcripts are eventually terminated. The 
element was identified by SI nuclease and primer extension 
experiments (Cattaneo et al., 1983, 1984).
The greater than genome length transcripts identified as 4.2kb and 
4.5kb species in the rat 2/130.4/TK4 system (Gough, 1983) and 3.5kb 
messages from infected chimpanzee livers (Cattaneo et al. . 1983, 
1984) must be produced from covalently closed HBV genomes. To be 
produced, RNA polymerase II must read through the polyadenylation 
signal at position 16 on its first round of transcription and 
terminate on the second cycle. The multiple initiation points of 
these genomic transcripts were mapped to around position 3063 by SI 
nuclease and primer extension studies (Cattaneo et al.. 1983) with 
transcription being driven by the core promotor at about position 
3050. This promotor was identified by in vitro and in vivo 
transcription studies (Standring et_al., 1983; Rail et al.. 1983) as 
a TAIA. box-like sequence. It is 10 times less strong than the SPII 
promotor on the basis of relative message levels (Cattaneo et al.. 
1983). These transcripts allow therefore for pre-core/core, core, 
and polymerase gene translation since separate messages for each have 
not been found and the genome messages are not spliced (Cattaneo et 
al., 1983). They may also act as pre-genome PNA molecules for HBV 
genome replication (Summers and Mason, 1982).
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The inference that the X gene has its own message (Gough, 1983), and 
that in the absence of HBV mRNA splicing must therefore have its own 
promoter, was substantiated by the experiments of Treinin and Laub in 
1987. By testing elements of DMA 5' to the X gene, using the CAT 
gene system for assessing promoter activity and mapping the 
initiation of transcription by primer extension, a TAIA like element 
at 2500 was identified. Like other mammalian viruses, HBV has an 
enhancer element (for review see Serf ling et al.. 1985), which has 
been mapped to around position 2500 by CAT assays on HBV CNA (Shaul 
et al.. 1985) and by "expression selection" of HBV genome elements 
(Tognani et al.. 1985). Ihe presence of this enhancer element is 
necessary for the activity of the core and X promoters, so it 
therefore must play a key role in viral genome replication and virion 
assembly.
The enhancer element has also been found to act in a tissue specific 
manner, as judged by CAT assays, with maximal activity in Alexander 
cells as opposed to non-hepatocyte derived lines such as HeLa cells 
(Shaul et al., 1985). The basis of this tissue specific nature of 
enhancer function has been investigated, and a glucocorticoid- 
responsive element has been identified at approximately 2015 using 
CAT assays to measure dexqmeth*sone stimulation of enhancer activity 
by various HBV genome fragments (Tur-Kaspa et al. (1986). The 
proposed element shares the consensus TGTTCT with other 
gluc#corticoid-responsive elements such as that present in Mouse 
Mammary Tumour Virus (Geisse et al., 1982) and may help to account 
for the tissue specific regulation of HBV transcription. Also it
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has been found that several liver-specific proteins bind to the HBV 
enhancer and upstream sequences (Shaul and Ben-Levy, 1987). The 
presence of some of the binding proteins is dependent on the 
differentiation stage of the hepatocyte, a core octamer sequence in 
the HBV enhancer appears also in the promotor of several liver- 
specific genes suggesting that the binding site and binding proteins 
contribute in some part to the tissue-specific expression of the HBV 
enhancer and hence to HBV gene expression. Furthermore, studies on 
transgenic mice harbouring integrated HBV sequences (Babinet et al., 
1985) indicate that S gene expression varies with hormonally driven 
liver tissue differentiation and that HBsAg levels were 5-10 times 
higher in male mice than female mice (Farza et al., 1987). These sex 
or other hormone mediated regulation mechanisms may account for the 
epidemiological data which indicates that HBV infected males are more 
likely to become carriers than females (Beasley and Huiang, 1984). A 
summary of transcriptional signals operating in the HBV genome can be 
found in figure 1.2.2.
1.2.5 Replication of the HBV genome
The process by which HBV and the other Hepadna viruses replicate 
their genomes can be considered as involving four major steps: (i) 
conversion of the asymmetric DMA of Dane particles to covalently 
closed circular DMA (cccCNA) within the nucleus of infected 
hepatocytes, (ii) transcription of cccDNA into the RNA pregenome by 
host RNA polymerase in virus cores, (iii) the reverse transcription 
of the mRNA pregenome using the virally encoded enzyme from a protein
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primer to yield the minus strand DMA, (iv) synthesis of the plus 
strand of DNA by copying the minus strand using an oligomer of viral 
RNA as primer (figure 1.2.4). Studies of intrahepatic DNA have 
revealed the presence of cccDNA forms of the viral genome (Mason et 
al., 1982; Weiser et al., 1983; Blum et al.. 1983; Miller and 
Robinson, 1984) which are located in the nucleus. Upon infection of 
ducks with DHBV, cccDNA is the first virus specific nucleic acid to 
be detected (Mason et al., 1983; Tagawa et al.. 1986), preceding the 
accumulation of viral RNA. Direct evidence implicating cccDNA as the 
first intermediate in replication is afforded by the observation that 
when DHBV cccDNA is density labelled in cultures of infected duck 
hepatocytes, the pattern of labelling is compatible with synthesis by 
reverse transcription but not by semiconservative replication 
(Tuttleman et al.. 1986), in that the density of the product is 
consistent with that of a RNA-DNA hybrid as opposed to a DNA-DNA 
duplex.
The 3.5kb genomic RNA transcriped from the core antigen promoter by 
RNA polymerase II serves as the template for reverse transcription. 
The 3' end of the transcript bears a terminal redundancy (R) which 
varies from 130 to 270 nucleotides among the hepadnaviruses (Ganem 
and Varmus, 1987), arising from the fact that the polyadenylation 
signal for HBV transcription is ignored for the first round of 
transcription, but obeyed the second time. Only one form of pre- 
genomic RNA is encapsulated into viral cores; the shortest form of 
3.5kb RNA is found exclusively in cores separated from other 5' end 
derivatives of the message (Enders et al.. 1985). The mechanism by
21
Figure 1.2.4 Replication of the HBV genome
A. Overall view of the process (from Murray, 1987).
B. (From Ganem and Varmus, 1987) Model for synthesis of the second 
(plus) strand of Hepadnavirus DNA, showing translocation of an 
oligoribonucleotide containing DR1 to the position of DR2 to 
initiate DNA synthesis. Boxed arrowheads represent DR elements, 
solid rectangles represent copies of the DR elements, thin wavy 
lines denote RNA, straight lines denote DNA, R indicates the 
terminal repeat in pregenomic RNA, r indicates the short 
terminal repeat in full-length minus DNA. The shaded 
eccentrically shaped symbol represents the putative protein 





















































































































































































































































































































which the sequence specific sorting of the whole 3.5kb message 
population is performed is unknown.
Reverse transcription as part of the replicative process is inferred 
by the observation that minus-strand DMA synthesis proceeds via an 
actinomycin D-insensitive process implying that the template is not 
DNA (Summers and Mason, 1982). Furthermore, duplexes produced under 
these conditions in sub-viral particles have a density in equilibrium 
centrifugation equivalent to RNA-DNA hybrids. Also, the fact that 
infected hepatocytes contain large quantities of unpaired minus 
strand DNA in cytoplasmic viral nucleocapsids suggests that HBV does 
not replicate via the classical semiconservative method (Summers and 
Mason, 1982).
The initiation site for minus strand DNA synthesis has been mapped to 
within the DR1 sequence by determining the position of the 5' 
deproteinated DNA strand (Mblnar-Kimber et al., 1984; Seeger et al., 
1986). It would appear likely that the 3' DR1 sequence, and not the 
5' DR1, of the pregenome contains the initiation point, since 
elongation of (-) DNA from the 3' DR1 allows uninterrupted synthesis 
across the entire genomic sequence giving rise to the minus DNA with 
a similar terminal redundancy called r. This predicted structure has 
been observed in virion DNA (Seeger et al., 1986) (figure 1.2.4).
Mapping of the 5' end of plus strand DNA placed the initiation site 
at the 3' end of DR2 (Seeger et al. , 1986; Lien et al.. 1986). 
There is a short oligomer of viral PNA covalently attached to the 5'
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end of (+) ENA, which when sequenced, revealed that the sequence was 
homologous to DR2 permitting priming by hybridisation to minus-strand 
DMA at this point. However, it was observed that the DR sequence was 
flanked by nucleotides from around DR1 rather than DR2 (Lein et al., 
1986). By mutagenising DR1 to make it distinguishable from DR2, it 
was found in the GSHV system that the RNA oligomer at the 5' end of 
(+) strand ENA bore the DR1 sequence not DR2 (Seeger et al.. 1986). 
To account for these observations it has been proposed that an 
oligomer containing DR1 from either 5 1 or 3' copy of R is 
transferred to basepair with the DR2 site in the minus strand.
Extension of the plus strand continues from DR2 of the minus strand 
until the protein primer at the 5' end of the template is reached. 
At this point the 3' terminally redundant sequence r of the minus 
strand displaces the 5' r sequence template allowing continuation of 
the plus strand elongation from the 3' end of the transferred minus 
strand. The resulting plus strands are of incomplete genome length 
and have variable end points. This model for HBV DMA replication is 
illustrated in figure 1.2.4.
1.2.6 HBV DMA integration and hepatoma
Although integration of HBV DMA in the livers of chronically infected 
patients correlates with the occurrence of hepatocellular carcinoma, 
any causal link between the former and the latter is yet to be 
established. Indeed, HBV infection is only one of several chronic 
inflammatory conditions associated with an increased risk of
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hepatoma, others include shistosomiasis and alcoholic cirrhosis. 
Therefore, the fact that HBV infection can cause chronic liver 
inflammation may be sufficient to explain the correlation between 
integration and hepatoma.
The most obvious molecular feature (in the light of findings with 
other mammalian viruses), which would allow HBV to act directly as an 
oncogenic virus would be if it possessed an oncogene. However, this 
seems unlikely since HBV DNA integrated in tumour cells does not have 
one universally uninterrupted reading frame (for review see Ganem 
and Varmus, 1987), which one would expect of an oncogene carrying 
virus. Furthermore HBV, or for that matter any other Hepadna virus, 
does not have genes that show any homology with normal cellular genes 
or known oncogenes (Varmus and Swanstrom, 1985).
Integration of HBV DNA may activate cellular proto-oncogenes by 
insertional mutation or deregulation of expression via its enhancer 
in an analogous manner to c-myc activation by certain tumour viruses 
(Varmus, 1984). One such report involves an HBV DNA. integration 
event such that the pre S region is fused in frame to a cellular 
sequence encoding a protein related to a steroid receptor and to the 
product of the v-erb-A oncogene (DeJean et al., 1986). The 
integration event characterised (denoted hap) correlated with the 
presence of several hepatomas and importantly gave rise to a 2.5kb 
transcript in the neoplastic tissues studied (de The et al., 1987). 
This suggests that the hap locus may relate in a causative manner to 
hepatocellular carcinogenesis.
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The possibility that HBV DMA integration may contribute to 
oncogenesis by causing a recessive mutation in a specific region of 
the host genome has also been investigated. Although an integration 
event may cause gross mutations, for example, in the case of a 12kb 
deletion in chromosome 11 near p!3 (Rogler et al., 1985), no 
mutation in a hepatoma has yet been mapped to a locus already 
duplicated in other neoplasia (Glaser et al., 1986). Other mutations 
in host DMA have been detected in hepatocellular carcinomas 
harbouring HBV sequences, but the integrated DMA is not adjacent to 
the mutations, and some of the mutations are not even neoplastic. 
(Ganem and Varmus, 1987).
The structure and nature of integrated HBV DMA in tumours and 
chronically infected livers has been studied extensively. A 
consensus has been reached as to the structure of viral and host ENA 
sequences involved in the integration and in the sequence 
characteristics of flanking host regions. There appears to be no 
specificity in host DMA sequence for integration (Ganem and Varmus, 
1987). However, the virus DNA appears to integrate preferentially at 
the sequences in or near the direct-repeats (DR), presumably using 




1.3.1 Structure of HBsAg and outer envelope
Amino acid sequence studies of the 226 residue protein product of the 
S gene by Peterson (Peterson, 1977; 1981) have led to a 
rationalisation of the higher order structure of the protein in terms 
of amino acid sequence. The amino acid sequence of the S gene HBsAg 
product is presented in Appendix B.
From the analysis of amino acid composition, it is apparent that 
there exists extensive hydrophobicity and a high proportion of 
proline and cysteine residues. These are consistent with early 
observations that HBsAg exists as a lipoprotein with complex tertiary 
structure (Sukeno et al., 1972; Was et al.. 1972; Steiner et al., 
1974). There are three possible glycosylation sites at aspargines 
number 3, 59, and 146; however, in the gp27 form of HBsAg only the 
146 residue is glycosylated (Peterson, 1981).
If one analyses the secondary structure of HBsAg using computer based 
predictions for local hydrophilicity (Hopp and Woods, 1981) and 
probability of a-helix or /?-sheet formation (Gamier et al.. 1978) 
certain features are revealed (figure 1.3.1) (Appendix C). The major 
regions of hydrophobicity are the N- (position 1-45) and Oterminal 
domains (position 150 - 226), and in an internal domain (position 80 
- 110). The relatively hydrophilic domains exist either side of the 
internal hydrophobic domain in positions 45 - 80 and 110 - 150. The
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Figure 1.3.1 Secondary structure prediction of HBsAg
The prediction for secondary structure indicated is based on the 
Garnier-Osguthorpe-Robson method (Gamier et al.. 1978), the 
prediction for hydrophobicity on the method of Hopp and Woods (1981). 
Both predictions were plotted using the University of Wisconsin 
Genetics Computer group (UWGCG) peptide structure program.
Predicted turns are represented by 180° turns in the plotted peptide 
sequence; the degree of hydrophobicity is indicated by the size of 
diamond positioned on the peptide sequence. The predicted sites of 
oligosaccharide attachment at 3, 59 and 146 are indicated by circles. 
Helices are shown with a sine wave, /3-sheets with a sharp saw-tooth 





second hydrophilic domain (110 - 150) contains the glycosylation 
site at 146 as well as the majority of the cysteine and proline 
residues. It is predicted that the N- and C-termini domains contain 
regions disposed to a-helix and /3-pleated sheet formation, whereas 
the two hydrophilic regions are areas of low secondary structure 
featuring multiple peptide chain turns dictated by prolines and 
glycines. If one evaluates propensity to form secondary structure on 
the basis of protein homology-based predictions (Coulson et al.. 
1987) (Appendix D) a similar picture emerges to that generated by 
physically based methods, in that the regions of greatest flexibility 
correlate with the two hydrophilic regions located either side of a 
hydrophobic a-helix, with the molecule well ordered in the 
hydrophobic N- and C-terminal domains. Thus from these various 
theoretical approaches it is possible to postulate that the extreme 
N- and C- regions of HBsAg associate with the lipid of Dane envelope 
or 22nm particles such that the two hydrophilic regions are situated 
internally or externally of the lipid envelope and in an aqueous 
environment, separated by a lipophilic region, making it necessary to 
postulate that the molecule must loop back into the membrane at this 
point (figure 1.3.2).
Evidence in support of these predicted features does exist. By 
trypsin protease mapping regions of exposed HBsAg in intact 22nm 
particles it was revealed that the region from 122 - 150 was exposed 
(teterson et al., 1982). Also the major antigenic region, as 
determined by studies using synthetic peptides to locate epitopes, 
was proposed as mapping to this exposed area (Lerner et al., 1981).
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Figure 1.3.2 Proposed orientation of HBsAg in outer envelope of
HBV
The HBsAg molecule indicated is a dimer between the glycosylated S 
derived peptide (gp26) and a pre S containing peptide. The 
hypothetical cystine bridges indicated maintain the integrity of the 
dimer as well as the peptides themselves.
The N-terminus of gp26 is associated with the hydrophobic lipid 
bilayer whereas pre S domains appear to be located externally. Of 
the two hydrophilic internal domains, the one situated nearest the C- 
terminus exists in the external aqueous environment. It harbours the 
glycosidic residue at position 146, B-cell antigenic determinants 
and most of the cysteine residues. The N-terminal hydrophilic domain 
is situated such that it is associated with the hydrophilic interior 
























It would seem most logical therefore to suggest that the hydrophilic 
domain 45 - 80 interacts internally with hydrophilic species rather 
than in an exposed external fashion.
Evidence in support of the lipid association of the N- and C-terminal 
domains comes from studies using a photoreactive probe for lipophilic 
peptide sequences. It was found that both the N- and C-termini were 
buried in lipid but the antigenically important region 122 - 150 was 
exposed to the aqueous environment (Gavilanes et al., 1982).
The importance of cysteine residues in maintaining higher order 
structure is indicated by their importance in maintaining the 
antigenicity of the protein. Upon reduction and detergent treatment, 
HBsAg in 22nm particle becomes 1000 times less antigenic (Yyas et 
al., 1972; Sukeno et al., 1972; Dreesman et al., 1973) than just 
detergent-disrupted aggregates. Furthermore it appears as though 
disulphide bonds allow HBsAg to exist as a dimer of p24 and gp27 in 
22nm particles which can be isolated antigenically intact and 
resolved into its protein components by reduction (Mishiro et al., 
1980). Although the 14 cysteine residues of HBsAg do appear to play 
an important role in the maintenance of inter- and intra-chain 
conformational integrity, the fact that HBsAg produced by S 
expression in yeast, can form 22nm-like particles prior to the 
formation of cysteine mediated interactions, suggests that protein- 
lipid interactions are of significance also (Wampler et al., 1985). 
Ihe exact nature of protein-lipid interaction has not been 
extensively studied, however the proportions of constituent lipids in
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the envelope have been deduced: phosphotidylcholine (-60%), 
cholesterolester (-4%), cholesterol (-5%) and triglycerides (-35%) 
(Gavilanes et al., 1982).
In the forms of HBsAg with pre S domains the hydrophilic pre S 2 and 
pre SI regions appear to be located in an exposed fashion in Dane 
particle envelopes and 22nm particles (Stibble and Gerlich, 1983; 
Heermann et al., 1984). The one possible glycosylation site in pre S 
at position 108 is occupied in the pre S2 containing gp33 and gp36 
containing proteins, but not in the pre SI - pre S2 containing gp42, 
whereas glycan attachment at the S gene encoded residue 146 exists in 
all pre S containing proteins (Heermann et al.. 1984). The pre S2 
domain is highly immunogenic, with antibodies occurring during 
natural infections against disulphide-bond independent epitopes 
(Neurath et al., 1984; Persing et al.. 1986a). Antibodies against 
pre SI domains have also been detected in the sera of HBV infected 
individuals (Theilmann et al., 1987) and in WHV infection (Shaeffer 
et al.. 1986). The immunogenicity of pre SI and pre S2 point to 
their relatively exposed location in the Dane particle envelope. A 
model for HBsAg location in the lipid bilayer of the HBV virion is 
presented in figure 1.3.2.
Relatively little is known about the arrangement of HBsAg dimer 
subunits in the outer envelope. The Dane particle envelope is 
believed to be composed of approximately 400 dimer subunits of 
diameter about 7.5nm, separated by about lOnm (Heermann et al., 1984; 
Aggerbeck and Peterson, 1985). The most abundant components
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comprising dimers are the p24 and gp27 proteins present in similar 
amounts (about 130 of each) in the virion, there are about 80 gp33 
or gp36 proteins and only about 60 pre SI containing gp42 or p39 
proteins per virion (Heermann et al.. 1984). In the serum located 
HBsAg aggregates such as 22nm particles, these relative levels of 
protein forms are maintained with the exception of pre SI containing 
peptides which are present at a very low level (Heermann et al., 
1984).
1.3.2 Function and biosynthesis of HBV outer envelope
It has been proposed that the means by which HBV and the other 
viruses of the Hepadna group achieve their tissue and host 
specificity of infection is by the action of the pre S region of the 
envelope (Neurath et al.. 1986b; Machida et al.. 1984).
Imai et al. in 1979 first indicated that gp36 HBsAg had the ability
to bind in vitro glutaraldehyde-polymerised human serum albumin
(GpHSA), whereas p24 and gp27 forms did not. Ihis suggested that the
55 amino acids of pre S2 had the ability to bind GpHSA. It has also
been observed that only hepatocytes from HBV susceptible animals
(humans and chimpanzees) have cell surfaces capable of binding GpHSA
(Thung and Gerber, 1981). A pre S2 peptide of 8kd (p8) released by
cleavage with cyanogen bromide has been shown to bind GpHSA, but not
non-human derived forms of the polymer, and monoclonal antibodies to
p8 aggregate Dane particles and also compete with binding between
gp33 and GpHSA (Machida et al., 1984). A model was proposed based on
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these results postulating that GpHSA acts as a bridge between HBV and 
target hepatocyte via specific receptors located on the hepatocyte 
and in the pre S2 region of the virus envelope. However, when 
similar experiments were repeated with naturally occurring pHSA, 
unlike glutaraldehyde cross-linked HSA, there was no HBsAg binding 
(Yu et al.. 1985), casting doubt on Machida's model. There is 
evidence that binding of HBV to hepatocytes is direct, involving the 
pre S region of the envelope (Neurath et al.. 1985). Using a series 
of non-overlapping synthetic peptides, representing the entire pre S 
region, to inhibit HBsAg-cellulose:Hep G2 cell interaction it was 
found that both pre SI and pre S2 regions are involved in virus 
association, with the pre S2 region playing an auxiliary role in pre 
SI mediated attachment (Neurath et al., 1986b). Given the role of 
pre S in virus targeting the use of anti-pre S antisera has proved 
successful in neutralising HBV (Neurath et al.. 1986a).
It is quite evident that the S gene product itself contains all the 
information necessary for the correct assembly and secretion of HBsAg 
in the form of 22nm particles, from studies with eukaryotic 
expression systems (for review see Murray, 1987). From 
electronmicroscopic evidence it appears as though 22nm particles are 
secreted via the constitutive secretory pathway (Gerber et al., 1974 ; 
Patzer et al., 1986) which is also involved in Dane particle assembly 
(Yamada et al., 1982). The use of HBV DNA transformed cell lines 
producing 22nm particles has confirmed this observation (Patzer et 
al.. 1984) and has indicated that the secretion of HBsAg is less 
efficient than the secretion of host proteins (Persing et al..
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1986b), with relatively slow glycan processing occurring at the rate 
determining Golgi apparatus stage (Patzer et al.. 1984). The initial 
event in HBsAg secretion is insertion into the endoplasmic reticulum 
(ER) via an N-terrninal signal sequence with nascent peptide emerging 
from associated ribosome into the lumen of the ER (Eble et al., 1986; 
Patzer et al., 1986). Soon after this an emerging hydrophobic domain 
is thought to anchor the peptide in the membrane with nascent 
protein now extending on the cytoplasmic side of the ER. The 
occurrence of a second internal signal sequence allows the 
cytoplasmically located peptide to re-enter the lumen of the ER (Eble 
et al.. 1986; 1987) (figure 1.3.3). In order that the proposed 
biosynthetic mechanism be consistent with HBsAg membrane topology 
(figure 1.3.1), it is necessary to postulate that after the second 
signal sequence another anchoring domain allows the C-terminus to be 
associated with the ER membrane. Transmembrane HBsAg molecules are 
then proposed to undergo aggregation in the lipid bilayer then bud 
off from the membrane encapsulating HBV core-DNA particles and DMA 
polymerase molecules, and enter the lumen (Eble et al.. 1986). Here 
the lipid composition of the envelope is altered from that of the 
original ER membrane, and envelope glycoprotein is modified in the 
golgi.
Although pre S sequences are not required for the membrane 
association of S gene translational products, it is clear that pre SI 
domains inhibit the secretion of pre Si-proteins and non-pre SI 
containing forms of HBsAg (Persing et al., 1986b; Standring et al.. 
1986; Chisari et al., 1986; Cheng et al., 1986). The point at
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Figure 1.3.3 HBsAg topagenesis
A. Model for the functioning of multiple different signal sequences 
(from Eble et al., 1987)
In the model, an N-terminal signal (filled circle) emerging 
from the ribosome (large oval) interacts with SRP (signal 
receptor protein (i), to initiate translocation of N-terminal 
domains (ii). An internal signal (filled bar) interacts with 
SRP (iii) and inserts within the membrane in a C-terminal end- 
first orientation (iv). Translocation of C-terminal domains by 
the internal signal (iv) completes the generation of the final 
tritopic configuration (v).
B. Model for HBsAg particle formation (from Eble et al.. 1986)
In this model particle formation is envisioned to begin with 
the transmembrane insertion of HBsAg peptides (i), depicted 
(for simplicity only) in a monotopic configuration. 
Subsequently, monomers undergo aggregation in the plane of the 
bilayer (ii), concomitant with or followed by exclusion of host 
membrane proteins and reorganisation of host lipid components. 
Budding (iii) and detachment (iv) from the membrane result in 


















which pre SI inhibits HBsAg secretion appears to be after the 
membrane insertion step, since pre Si-proteins are glycosylated. 
Retardation of secretion by pre SI is dosage dependent suggesting 
that inhibition occurs during sub-unit mixing during Dane particle 
formation (Standring et_al., 1986; Chency et al.. 1986). The pre Si- 
proteins are the only surface proteins to be acylated, harbouring 
covalently linked myristic acid at their N-termini (Persing et al.. 
1987); such a modification would explain their restricted movement 
through the secretory machinery with the acyl group either anchoring 
pre SI in the membrane or inhibiting movement through the bilayer. 
Thus such restricted pre Si-protein translocation could regulate 
envelope (and so virion) formation and play a role in phasing 
envelope synthesis with other viral morphological events. The fact 
that HBsAg in 22nm particles is more efficiently secreted than that 
in Dane particles which possess far higher levels of pre SI proteins 
is consistent with the proposal of a regulatory role for pre SI 
(Heermann et al., 1984).
1.4 Immunology of HBsAq
1.4.1 Nature of antigen structure
The differences between the humoral (B-cell) and cellular (T-cell) 
mediated parts of the immune system are reflected in the nature of 
immunogens that trigger them. For every immunogenic particle, for 
example a virus, there exist different T-cell and B-cell specific 
epitopes (Mitchison, 1971). Viral epitopes specific to B-cells are 
presented to the membrane immunoglobulins directly in a
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conforrationally intact form (Roitt et al. f 1985). In contrast T- 
cells (T-cytotoxic CD8+ or T-helper CD4+) are only triggered by non- 
native, intracellularly processed antigens presented on the surface 
of a cell with the correct Major Histocompatibility Complex (MHC) 
molecules (Katz et al.. 1973; Ziegler and Unanue, 1981). In this 
way the two populations of responding cells can be triggered by 
different features of the same virus or even the same protein (Roitt 
et al.. 1985). The expansion of a specific T-helper (CD4+) cell 
clone after antigen presentation by a macrophage or B-cell 
(Lanzavacchia, 1985) will maximise the expansion of the B-cell clone 
that recognised a feature of the intact antigen. This situation has 
been encountered from studies of immune responses to viruses such as 
influenza (Townsend et al.. 1985), foot and mouth disease virus 
(Francis et al.. 1987) and HBV (Milich et al.. 1987a; 1988; Vento et 
al. r 1987). Recently two models have been proposed to identify the 
amino acid sequences of antigen involved in T-cell recognition. De 
Lisi and Berzofsky have found that a large proportion (70%) of T- 
lymphocytes appear to react with a-helical amphipathic structures 
contained within the amino acid sequences of antigen proteins 
(Margalit et al., 1987; De Lisi and Berzofsky, 1985). On the other 
hand Rothbard, McMichael and Townsend point to the existence of a 
four to five-amino acid sequence motif in a large number of T-cell 
antigenic determinants (Townsend et al., 1986; Rothbard, 1986). 
This motif is composed of a glycine or a charged amino acid residue 
in the first position, followed by 2 or 3 hydrophobic residues which 
are followed in turn by either a glycine, a polar, or a charged 
residue in the last position.
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It would appear that most B-cell epitopes are conformationally 
determined and can be imagined as discontinuous epitopes being 
dependent upon the spatial arrangement of two or more peptide 
regions. Continuous epitopes are regions of short peptide sequence, 
therefore less dependent on tertiary and secondary structure, 
existing at the loops and protruding regions of proteins (Benjamin et 
al., 1984; Barlow et al.. 1986). There have been few antigen- 
antibody complexes studied directly by X-ray diffraction, examples 
include epitopes of hen-egg white lysozyme (Amit et al., 1986; 
Sheriff et al.. 1987) and of influenza virus neuraminidase (Colman et 
al. . 1987). Each of the studies revealed discontinuous epitopes all 
of which covered a large proportion of the surface area of the 
molecule.
In an attempt to define what chemical features of a peptide region 
predispose it to be an epitope, Hopp and Woods (1981) analysed 
protein structure and correlated it to antigenicity. They concluded 
that the degree of exposure of a region to the external environment, 
assessed by a preponderance of hydrophilic residues, determines its 
B-cell antigenicity. Therefore, factors like hydrophilicity, degree 
of flexibility and probability of situation at the surface of the 
protein, appear to be important. The testing of these theoretically 
based predictions has been afforded by representing an entire protein 
antigen (of known structure) by short synthetic peptides and 
assessing the proportion of antibodies in the native protein 
antiserum which recognise a particular peptide. Tnis approach has 
largely vindicated earlier predictions since the most reactive 
peptides in studies mapped to positions of maximum mobility,
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accessibility, convex shape (Geysen et al.. 1987; Barlow et al., 
1986; Thornton et al.. 1986; Novotnv et al.. 1986). Surfaces which 
displace bound water, such as those of negative electrostatic charge 
and convex shape, reduce stearic hindrance to antibody-epitope 
binding (Geysen et al.. 1987). The peptide mapping approach to 
epitope definition is biased in favour of continuous epitopes, since 
it is always point specific and unlikely to locate the larger 
discontinuous epitopes (Benjamin et al.. 1984). The use of site- 
directed mutagenesis (SEM) (Zoller and Smith, 1983) in conjunction 
with molecular modelling to test changes in predicted structure on 
antigenicity allows an alternative approach to epitope definition 
(Rees and de la Paz, 1986). This approach was used to test the 
predictions of area size and necessary electrostatic charge of an 
epitope of hen-egg white lysozyme; the results obtained confirmed 
the size of the epitope and cast doubt on the iinportance of 
electrostatic charge in the region, since substitution of amino acids 
comprising the epitope with ones of different charge had little 
effect (Roberts et al.. 1987).
1.4.2 Immunochemistrv of HBsAq
Serologically, HBsAg has one group specific determinant a and 2 sets 
of mutually exclusive determinants d or y (Le Bouvier, 1971) and w or 
r (Bancroft et al., 1972) giving 4 serotypes adw, ayw, adr and ayr. 
These strain specific serotypes show a stable geographical 
distribution with ayr subtype occurring very rarely and only in Asia 
(Sobeslavsky, 1978) (figure 1.4.1). In a natural infection most of
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Figure 1.4.1 Geographic distribution of HBsAg subtypes (from
Sobeslavsty, 1978)
The relative proportion of total HBsAg as subtype adw, ayw or adr is 
indicated by the proportion of pie chart. HBsAg of subtype ayr 
occurs very rarely and only in Asia.
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the antibodies are a-specific with the subtypic population 
contributing little to protective immunity (Murphy et al., 1974; 
McAuliffe et al.. 1980). Using the antigenicity predictions of Hopp 
and Woods (figure 1.3.1) in conjunction with synthetic peptide 
epitope mapping, the a-group area has been located between amino acid 
residues 138 and 149 (Prince et al., 1982), 139 and 147 (Bhatnagar et 
al. f 1982). The a-group is composed of more than one epitope since 
panels of non-cross reacting a-specific monoclonal antibodies exist 
(Tedder et al., 1984; Swenson et al., 1988). The majority of the a 
epitopes are conformationally sensitive and therefore likely to be 
discontinuous since perturbations in tertiary structure caused by 
reduction or detergent treatment drastically reduce antigenicity 
(Vyas et al., 1972; Sukeno et al., 1972; Dreesman et al., 1973). 
Furthermore, although the linear peptides that identified the a- 
region reacted with a-antiserum the antigenicity was far less than 
that of native HBsAg (Bhatnager et al., 1982). The only attempts 
that have been made to postulate possible conformations have involved 
using a-region peptides cyclised about specific cysteine residues to 
test whether these represent native conformations (Brown et al.. 
1984; Dreesman et al., 1982). In both cases cyclisation about 
cysteines 139 - 147 (Brown et al.. 1984) and 124 - 137 (Dreesman et 
al. r 1982) increased antigenicity, but not to the level of native 
antigen. Disulphide bridge contribution to a-epitope structure has 
also been demonstrated by the production of monoclonal antibodies to 
the disulphide-bond dependent a-epitopes (Swenson et al., 1988 ; 
Antoni and Peterson, 1988). The involvement of the glycan group at 
position 146 was discounted from contributing to a-antigenicity upon
47
its removal without loss of reactivity to anti-a-sera (Skelly et 
al., 1978).
The contribution of the cell mediated immune system to the production 
of anti-HBsAg antibodies was first demonstrated by Roberts et al. 
(1975), this T-cell priming has been shown to be MHC class II 
restricted (Milich et al.. 1984). A short peptide region of HBsAg 
(24 - 27) has been identified as a possible MHC-restricted, T-helper 
cell and cytotoxic cell determinant (Celis et al., 1988), antibodies 
primed by the region were specific for HBsAg. The sequence of the 
peptide described was comparable to those proposed as T-cell epitopes 
by De Lisi and Berzofsky (1985) and Rothbard and collaborators 
(Townsend et al.. 1986; Rothbard, 1986; section 1.4.1). Also a 
single 10-residue pre-Sl peptide (12 - 21) can prime T-cell help for 
antibody production to multiple epitopes within the pre-Sl, pre-S2 
and S regions of HBsAg under H-2 restriction in mice (Milich et al., 
1987c).
The nucleocapsid (HBcAg) can induce antibody responses via a T-cell 
independent pathway (Milich et al., 1986) and is highly immunogenic 
during HBV infection. This is consistent with the observation that 
HBcAg can protect chimpanzees from HBV challenge (Murray et al., 
1984; 1987). The core antigen can also prime B-cells for anti-HBsAg 
antibody production by activation of T-helper cells in a MHC class II 
restricted fashion (Milich et_al., 1987a; 1988). The use of 
synthetic peptides has revealed that a region from residues 85 to 140 
determines the T-cell reactivity of HBcAg with different epitopes
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within the region being specific for different haplotypes. One 
particular epitope, contained in a 120 - 140 peptide, was capable of 
priming anti-HBcAg, anti-HBsAg and anti-Pre S antibody production in 
a MHC class II restricted fashion (Milich et al. . 1987b). As well 
as activating T-helper cells HBcAg is also capable of activating T- 
cytotoxic cells through its expression on the surface of infected 
hepatocytes and recognition in conjunction with MHC class I proteins 
(Mondelli et al., 1982)
1.4.3 HBsAq subtype
A compound subtype of an HBV serum represents a situation where both 
subtypes, of a mutually exclusive pair, are present in the serum of 
an infected individual (Nonderfelt and Le Bouvier, 1973; Mazzur et 
al., 1975). These compound subtype sera, which are present at very 
low levels, may be due to infection by more than one virus of single 
subtype, giving rise to the phenotypic expression of a compound 
serotype (Paul et al.. 1986; van Kboten Kok-Doorshadt et al., 1972; 
Okamoto et al., 1987a), or to more than one subtype existing on a 
single HBsAg particle (Paul et al., 1986). The mechanism that gives 
rise to a compound subtype particle is proposed to involve 
recombination between the genomes of different subtype HBV to produce 
a hybrid S gene which when expressed gives rise to a particle of 
compound subtype (Nordenfelt and Le Bouvier, 1973).
Determination of the d/v subtype appears to be due to the presence or 
absence of several specific epitopes, since there are panels of d-
49
specific and y-specific monoclonal antibodies which do not cross 
react (Swenson et al.. 1988). Interestingly, these monoclonal 
antibodies are also specific for disulphide dependent or independent 
epitopes. The region of HBsAg comprising the subtype determining 
region has been mapped in a similar way to that of the a-region, 
using Hopp and Woods antigenicity predictions to synthesise peptides 
representing hydrophilic and variable regions of the protein, raising 
antisera, and then determining the subtype specificity of the 
antisera (Gerin et al.. 1983). Such an approach has mapped the d/y 
region to between amino acids 110 - 139. Prince et al (1982) using 
the same approach found that a peptide representing adw from between 
138 - 149 was sufficient to elicit a d-specific antiserum. By 
expressing various regions of the S gene in E. coli then subtyping 
antisera to antigen produced (MacKay et al., 198 Ib) mapped d- 
specific regions to between 4 and 121. It is apparent therefore that 
epitopes for the d/y system appear to co-occur, with a epitopes in 
the hydrophilic domain and, that given their disulphide bond 
dependence, it is likely that some of these epitopes are 
discontinuous, and distributed about the whole of the hydrophilic 
area.
The genomes of HBV of all 4 serotypes ayr (Okamoto et al., 1986), ayw 
(Gallbert et al., 1979; Bichko et_al., 1985), adr (Ono et al.. 1983; 
Can et al., 1984; Fuj iyama et al., 1983; Kobayashi and Koike, 1984; 
K Yokoyama, personal communication), and adw (Valenzuela et al.. 
1979; Ono et al., 1983) have been sequenced along with that of a 
virus which was originally thought to have a compound subtype adyw. 
but has been designated ayw2 (Pasek et al., 1979; Pugh et al..
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1986; this thesis). If one compares the peptide sequence of HBsAg 
proteins from different subtypes (figure 1.4.2) one observes residue 
positions that correlate to some degree with the presence of a 
particular subtype. These correlations have been used as starting 
points for the investigation of the role of a particular residue in 
conferring an epitope that determines subtype. The difference in 
amino acid at position 122 determines the binding of a d-(lysine) or 
y-(arginine) specific monoclonal antibody to adr and ayr proteins 
(Okamoto et al., 1986). Also differences at position 160 can dictate 
the binding of a w and a r specific monoclonal antibody to adr and 
ayw proteins (Okamoto et al.. 1987b). If the lysine of adw HBsAg at 
position 122 is subjected to reductive methylation, reactivity to a 
d-specific monoclonal antibody is decreased (Peterson et al.. 1984). 
Replacement of the cysteine at position 121 (present in all serotypes 
of HBsAg) with a serine by site-directed mutagenesis, results in a 
decrease in reactivity to an a-specific monoclonal antibody as well 
as to a y-specific monoclonal antibody (Antoni and Peterson, 1988). 
These experiments infer that the area around position 122 is 
important in determining the nature of d/y epitopes, and of at least 
one discontinuous a-epitope. These experiments therefore represent 
an initial investigation into the structural basis of HBsAg 
serotypes.
1.5 Aims and Rationale of Project
The molecular basis of serotypic variation in HBV is at least partly 
due to differences in HBsAg structure. This proposal has been 
arrived at by indirect and direct means. It is possible to correlate
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Figure 1.4.2 Comparison of peptide sequences of HBsAg of different
subtypes
The genomes of HBV of all serotypes have been sequenced and the 
peptide sequence of HBsAg deduced. The consensus peptide sequence is 
represented by capital letters and amino acids at variable positions 
by small letters.
ayw2 (adyw) (Pasek et al.. 1979; Pugh et al., 1986), avw (Galibert 
et al.. 1979; Bichko et al.. 1985), avr (Okamoto et al.. 1986), adr 
(Ono et al.. 1983; Can et al.. 1984), adr4 (Fujiyama et al.. 1983), 
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certain amino acids at specific positions in HBsAg with the subtype 
of the virus (figure 1.4.2, section 1.4.3). Direct evidence comes 
from serotypic mapping using synthetic peptides (Gerin et al.. 1983), 
and mutational approaches which have implicated certain amino acids 
in subtype specific epitopes (Peterson et al., 1984; Okamoto et 
al., 1986; Okamota et al.. 1987a, b; Antoni and Peterson, 1988).
One of the aims of this thesis was to assess the contribution of 
three amino acids occurring at various positions in determining d/y 
subtype specificity. The residues at position 122 correlate exactly 
with d/y variation, at 134 correlation is less than exact. Both 
sites have been implicated in d/y subtype determination by 
experimental means (Gerin et al. . 1983). Position 113 exhibits amino 
acid variation in correlation with w/r subtype variation, but not 
with d/y so would represent a negative control for the effect of 
mutations on d/y subtype. By the use of oligonucleotide site- 
directed mutagenesis (Zoller and Smith, 1983) the effect of 
substitutions of amino acids at positions 113, 122, and 134 on the 
subtype of HBsAg (Pasek et al.. 1979) (subtype ayw) was examined. 
Outlined in figure 1.5.1 are the nucleotide substitutions in the S 
gene necessary for the desired substitution of y to d specific amino 
acids. The effect of these mutations on the subtype of the yeast 
expressed protein (Murray et al., 1984) were assessed using an 
immunoprecipitation based subtyping assay, in this manner the 
contribution of the substituted amino acids in the determination of 
d/y subtype was assessed (Burrell et al., 1978).
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Figure 1.5.1 Subtype variable amino acids substituted by Site- 
Directed Mutagenesis
The mutations made in adw2 HBsAg at sites of amino acid variation are 
indicated by boxes. The corresponding changes in nucleotide 
sequence, brought about by oligonucleotide-mediated, site-directed 





























































































































































It has been emphasised previously that HBsAg owes much to 
conformational integrity for its antigenicity. However, in the 
absence of extensive structural studies (such as X-ray diffraction), 
the spatial arrangement of the a-antigenic region is largely unknown. 
Shown in figure 1.5.2 is a summary of the information derived from 
synthetic peptide based and mutational studies of the immunoreactive 
region of HBsAg. Using mutants in the a-region it was hoped that 
amino acids important in determining a-antigenicity could be 
identified. The work of Brown et al. (1984) and Dreesman et al. 
(1982) duplicated the cysteine residues 139 and 147, 124 and 137 in 
contributing to antigenicity through the formation of disulphide 
bridges. To assess the importance of these cross linkages, 
substitution of the cysteines at 124 and 147 for serine in yeast 
expressed HBsAg was performed. The contribution of prolines to the 
spatial arrangement of polypeptides is well known - they introduce 
turns into the a-carbon backbone of proteins (Gamier et al.. 1978). 
The substitution of proline 142 for glycine and isoleucine was made 
to determine the contribution of the residue, and by inference the 
turn at 142, to the antigenicity of the a-region.
The influence of the substitutions 122arg ~" lys and 134tyr ~* phe on 
a-antigenicity were also assessed. Both of these residue positions 
are located in the a-region, but are not important for a-antigenicity 
since the amino acids present vary between subtypes with no effect on 
HBsAg antigenicity (McAuliffe et al.. 1980). This allowed one to 
assess the contribution of non-specific amino acid substitutions on 
a- antigenicity.
57
Figure 1.5.2 Antigenic region of HBsAg
The peptide sequence of HBsAg, deduced from the gene, cloned by Pasek 
et al. (1979) from position 101 to 150 is shown. Represented above 
it is a summary of the results from examinations of HBsAg B-cell 
antigenicity using synthetic peptides. The region of a-antigenicity
Wooc/5
has been mapped to between positions 141 and 146 (b) by/y«o,>-^ et al. 
(1981), 138 and 149 (c) by Prince et al. (1982) , 139 and 147 (f,g) by 
Bhatnager et al. (1982) and Brown et al. (1984), 122 and 137 (e) by 
Dreesman et al. (1982). The cyclisatin of peptides e and g about 
cysteines 124, 137 and 139, 147 respectively, increases 
immunoreactivity. The region of HBsAg implicated in determining d/y 
subtype reactivity has been located by Gerin et al. (1983) (a) to 
between 110 and 139 (125 and 139). The substitution of cysteine with 
serine at position 121 (d) by Antoni and Peterson (1988) resulted in 
little change in HBsAg reactivity to an anti-HBsAg serum but altered 
antigen reactivity with several a-specific monoclonal antibodies.
The positions of the amino acid substitutions implicated are 


























































































































































2. MATERIALS AND METHODS
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2.1 Materials
2.1.1 Strains and vectors
E. coli KL2 strains
Relevant Genotype Use Reference
HB101 hsdS20 R general host
EMH71-18
recA 13, ara!4, for plasmid 
proA2 , lacYl, gal cloning 
K2 , rpsL20, (SM) R, 
xyl-5. nrtl-1, 
supE44, A~
A(lac-pro), SupE, plating cells 
thi. /F 1 , proA+B+ , for EMH71-18 
lacZ AMIS, laclq rautL trans-
fections




NM522 hsd As derivative host for M13 Gough and
of EMH71-18 irp8 phages Murray (1983)
EMH71-18 
rautL
as EMH71-18 except transfection
mutL::TnlO host for SCM 
produced M13 
np8 duplexes
Kramer et al 
(1984a)
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Murray et al, 
(1984)
replication origin, shuttle vector. 
FH05 promoter and Allows egression 










M13 itp8 - Cloning vector Messing and





lOg Difco Bacto Tryptone
5g Difco Bacto Yeast extract
lOg NaCl
Made to 1 litre, and adjusted to pH 7.2
]>aqar
As L-broth, but containing 15g agar per litre.




Made to 1 litre.
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Minjjnal medium
300ml Water agar 
80ml 5 x Spizein salts 
4 ml 20% (w/v) Glucose 
100/il 2mg/ml Vitamin Bl
2 x TY medium
16g Bacto Tryptone
lOg Bacto Yeast extract
5 g Nad
Made to 1 litre
Antibiotics




10 g Difco Bacto Yeast extract
20g Difco Bacto-peptone
20g Glucose
10ml Adenine Sulphate 4 mg/ml
Made to 1 litre.
YPDA. agar
YPDA containing 20g per litre agar.
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Yeast minimal medium
6.7g Difco yeast nitrogen base without amino acids
20 g Glucose
20mg Amino acid/supplement as required
20g Agar
Made to 1 litre
Supplements for minimal medium: stock at 4mg/ml in H20.
Final concentration of 20mg/l. supplements were: leucine,
histadine, tryptophan and uracil.
Synthetic medium for expression
In order to control the concentration of culture medium phosphate, a 








Made to 1 litre
to every litre of synthetic minimal medium 2ml "Vitamin Cocktail" and 






















The medium was supplemented with the relevant amino acid or purine 
at a concentration of 20mg/litre.
"high" phosphate medium contained Ig/litre monobasic potassium 
phosphate.







Denhardt's solution, 10X 
0.2% (w/v) BSA
0.2% (w/v) Polyvinyl-pyrrolidine (PVP) 
0.2% (w/v) Ficoll 400 DL
TBE, 10X
0.1M Tris.HCl pH 8.3 
89mM Boric acid 
2mM EDIA
ICtaM Tris.HCl pH 8.0 
lirM EDTA.
ETB









6mM K2HP04 pH 7.0
0.15M NaCl
RIP buffer
0.5% (w/v) BSA in PBS
(0.1% (w/v) Sodium azide as preservative)
2.1.4 Enzyme buffers
IPX high salt restriction endonuclease buffer: (For use with BamHI) 





IPX low salt restriction endonuclease buffer: (For use with Clal) 
as above with the omission of 0.5M NaCl
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T4 DMA lioase buffer:
IPX blunt lioation buffer 




5X sticky liqation buffer




IPX T4 l^A polynucleotide kinase buffer 




2.1.5 Solutions for dideoxv-nucleotide DNA sequencing















































KLenow mix (per clone)
4/zCi a-[ 35S]-dATP (Amersham, 600Ci/mM)
1.5U E. coli DMA polymerase I KLenow fragment (Boehringer)
0.8/ul lOmM DTP
6.5jLtl lOmM Tris.HCl pH 8.5
Single Dideoxy-nucleotide Tracking
Primer mix




3/xl of the primer mix added to 3/il of template (0.3/ig), the 
composition of termination chase, and KLenow mixes were the same as 
those used for complete sequencing.
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Extended DNA sequencing





0.1% (w/v) Xylene cyanol 
0.1% (w/v) Bromophenol blue 
lOmM EDIA 
in 1ml deionized Formamide.
Polvacrylamide gel separation of dideoxy-nucleotide sequencing 
reaction products
Gels were made as follows: 
17g Urea 
6ml 40% (w/v) Acrylamide (38% (w/v) Acrylamide/2% (w/v)
Bisacrylamide) 
4ml 10 X TBE
0.24ml 10% (w/v) Ammonium persulphate 
40/zl N,N,N', 'N' -tetramethyetiiylenediamine (TEMED) 
Final volume 40ml with H20.
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Polvacrvlamide gel for separation of ENA oligonucleotides
Gels were made up as follows: 
21g Urea 
25ml 40% (w/v) Acrylamide(38% (w/v) Acrylamide/2% (w/v)
Bisacrylamide 
5ml 10 X TBE
0.35ml 10% (w/v) Ammonium persulphate 
40/Lil TEMED 
Final volume 50ml with H2O.
Solution for fixing DMA in urea-tX3lyacrvlamide gels 
10% (v/v) Methanol 
10% (v/v) Acetic acid 
in H2O.
2.1.6 Solutions for protein techniques
For a 13% (w/v) SDS-polyacrylamide gel, the solutions were:
Separating gel
23.2ml 30% (w/v) Acrylamide
23.2ml 0.8% (w/v) Bisacrylamide
6.25ml 3M Tris.HCl pH 8.8
0.4ml 10% (w/v) SDS






1.9ml 1M Tris.HCl pH 6.8
0.15M 10% (w/v) SDS
9.35ml dH2O
0.15ml 10% (w/v) Ammonium persulphate
Electrophoresis buffer IPX 
0.2M Glycine 
0.25M Tris.HCl pH 8.0 
0.1% (w/v) SDS
Loading buffer




0.1% (w/v) Bromophenol blue
Ponceau S stain





20nM Tris.HCl pH 8.1
0.14M Glycine
in 20% (v/v) Methanol.
10 X TS




Purified HBsAg produced from pHIN/G~2 expression in yeast was 
obtained from either the Green Cross Corporation (Osaka) or Biogen 
Inc.
The Green Cross material (>99% of total protein 698jLig/ml) in 20mM 
sodium phosphate pH 7.2, 0.1% (w/v) sodium azide. The Biogen 
material was of similar purity (0.6mg/ml) and stored in PBS with 0.1% 
(w/v) sodium azide.
Human HBsAg was kindly provided by Dr J Peutherer, Department of 
Bacteriology, Edinburgh University. HBsAg was purified from carrier 
serum to 70 - 80% of total protein, using the method of Burrell
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(1975). This purified material was labelled with 125I by the 
iodogen based process (Burrell, 1973).
Preparation of Antisera
Anti-HBsAg mouse monoclonal antibody (clone 1E6) was kindly provided 
by the Green Cross Corporation. HBsAg of subtype adr had been used 
to immunise mice and antibodies from clone 1E6 purified to a level 
of >99% total protein (50(tyig/ml) and stored in lOmM acetic acid, pH 
6.7, 60mM NaCl, 0.002% (w/v) sodium azide, 1% (w/v) mannitol.
Ihe antiserum NRA/B7-4B was kindly provided by Dr P Wingfield (Biogen 
Inc) and prepared in the following manner: HBsAg (100/zg) produced 
and partially purified from yeast as in Murray et al. (1984) was 
denatured by incubation in 1% (w/v) SDS, 60mM DTT at 80 °C for five 
minutes. The antigen preparation was then dialysed against PBS to 
remove SDS and DTT and used to immunise New Zealand white rabbits 
subcutaneously in Freund's complete adjuvant, the animals were 
boosted with the same preparation after five weeks, then again after 
two weeks.
Anti-human HBsAg sera were obtained from Dr J Peutherer. The 
monospecific anti-y and anti-d antisera were prepared as follows: 
purified human HBsAg (100 - 150jzg) was used to immunise New Zealand 
white rabbits subcutaneously in Freund's complete adjuvant, then 
after 6 weeks the animals were re-djrarrunised and, if necessary again 
two weeks later. Antibodies which were a and subtype specific were
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removed by absorbing against antigen of the opposite d or y serotype. 
This absorbtion was carried out using lOOjug HBsAg for 16 hours at 4°C 
followed by centrifugation at 30,000 x g for 10 minutes at 4°C to 
remove antibody-antigen complexes. This process was then repeated a 
further two tiines.
Donkey anti-rabbit IgG and sheep anti-mouse IgG were obtained from 
the Scottish Antibody Production Unit.
2.2 Methods
2.2.1 DMA methods
Phenol extraction of nucleic acids
Distilled phenol was equilibrated with 1M Tris.HCl pH 8.0 prior to 
use. Equal volume of phenol was added to aqueous nucleic acid 
solution then mixed vigorously by vortexing. Following centri­ 
fugation at 17,000 x g for 10 minutes, at room temperature, the upper 
aqueous layer was removed.
Ethanol precipitation of DMA
Ethanol (98% (v/v)) stored at -20 °C was added to aqueous solutions of 
DMA in a 2.5:1 volumetric ratio; 3M sodium acetate pH 5.2 was also 
added at a volume 0.1 of that of the DMA solution. The mixture was 
vortex mixed and incubated at -20°C for 10 minutes. Precipitated
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DMA was recovered by centrifugation at 4 a C at 17,000 x g for 15 
minutes. The pellet was then washed with 70% (v/v) ethanol at -20°C 
and dried under vacuum.
Restriction endonuclease digestion
Enzymes were purchased from Fharmacia, Boehringer-^annheim, and New 
England Biolabs. DMA was digested at 37 °C for up to 90 minutes in IX 
restriction endonuclease buffer and enzyme added to give a ratio of 
10U:lug DMA. Reactions were terminated by phenol extraction and DMA 
recovered by ethanol precipitation.
DMA liqation
T4 ENA ligase was purchased from Boehringer. Ligations between DMA 
bearing cohesive ends were carried out for 16 hours at 15 °C by T4 DMA 
ligase (O.lU/jug ENA) in IX sticky ligation buffer at a concentration 
of 5 - 30jLtg/ml.
Blunt end ligations were carried out at 15 °C for 16 hours by T4 ENA 
ligase (lU//zg) in IX blunt ligation buffer at a ENA concentration of 
200 - 500/zg/ml.
Transformation of
M13 RF DNA: L-broth (100ml) was inoculated with 1ml of a stationery 
phase culture of NM522, EMH71-18 mutL or TG1 cells and grown to
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OD600nm °- 2 bY shaking at 37°C. Cells were then pelleted by 
centrifugation at 4,000 x g for 5 minutes at 4°C, and resuspended in 
10ml ice-cold 0.1M CaCl2 and left on ice for 30 minutes. After 
repelleting and resuspension in 2ml ice-cold 0.1M CaCl2 , 0.2ml of 
cell suspension was added to M13 RF or single-stranded ENA in glass 
tubes and left on ice for 30 minutes. The cells were heat-shocked at 
42°C for 4 minutes and plated in 3.5ml BBL top with 40jul of 
stationery phase cells on minimal plates. Isopropyl-£-D- 
thiogalactopyranaside (IPTG) (20jL*l) and 5-Bromo-4-chloro-3-indolyl-/?- 
D-galactopyranoside (X-gal) (30/il) were added to BBL top to detect 
/3-galactosidase positive M13 clones. IPTG and X-gal were stored at a 
concentration of 20mg/ml in diinethylformamide at -20°C.
Plasmid DMA: The preparation of competent cells was performed as 
above except that the cells resuspended in 2ml CaCl? were left for a 
further 60 minutes on ice instead of being used immediately. The 
heat-shocked cells were diluted into 1ml L-broth and incubated at 
37°C for 60 minutes. The mixture (0.2ml) was then spread on 
selecting L-amp plates.
Transformation of S. cerevisiae_ using sphaeroplast method
The method used was that developed by Beggs (1982). A culture 
(50ml) of DBY746 was grown in YPDA at 30°C to OD60onm °- 5 then 
centrifuged at 4,000 x g for 5 minutes at room temperature, and 
cells resuspended in ice-cold, sterile dH2O (20ml). After re- 
pelleting, cells were resuspended in 1M sorbitol, 25mM EDTA pH 8.0,
79
50mM DTT (20ml) and incubated at 30°C with gentle shaking for 20 
minutes. Cells were pelleted, washed with 1.2M sorbitol (ice-cold) 
and resuspended in 1.2M sorbitol, lOmM EDTA, 0.1M sodium citrate pH 
5.8 (20ml) containing 1% (v/v) /3-glucuronidase (Sigma H-I) then 
incubated for 90 minutes at 30 °C. Sphaeroplasts were pelleted and 
washed 3 times with ice-cold 1.2M sorbitol then resuspended in 1.2M 
sorbitol, lOmM CaCl2 (0.5ml). DNA was added to SOjiil of sphaeroplast 
suspension to give a final concentration of 20jiig/ml, and incubated at 
room temperature for 15 minutes. Then lOmM Tris.HCl pH 7.5, lOmM 
CaCl2/ 10% (w/v) polyethylene glycol 4000 (PEG 4000) solution (0.5ml) 
was added and sphaeroplasts immediately pelleted by centrifugation at 
17,000 x g for 2 minutes at room temperature. Sphaeroplasts were 
gently resuspended in YPDA (lOO/xl) containing 1.2M sorbitol and 
incubated at 30°C for 15 - 60 minutes. Dilutions of sphaeroplast 
suspension were made in 1.2M sorbitol and plated on selecting 
minimal plates in 3% (w/v) minimal agar. Colonies of transformed 
cells appeared after incubation for 4 days at 30°C.
Labelling DMA by Random Priming
The method used was that of Feinberg and Vogelstein (1983; 1984). 
The DMA fragment of interest was purified by electrophoresis through 
low-gelling temperature agarose (Seakem) and the desired band cut out 
(-1/zg). The agarose was added to dH20 in a ratio of 3ml dH20:lg 
agarose, then placed in a 100°C water bath for 7 minutes before being 
incubated at 37°C for 10 to 60 minutes. The labelling reaction was 
carried out using 35.5/il of agarose slurry added to 10/il oligo-
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labelling buffer (OIB) , 2/zl BSA (lOmg/ml) , 50/LiCi a-[ 32P]-dCTP 
(Amersham, 3000Ci/niM) and 1/il (5U) E. coli DNA polymerase I KLenow 
fragment (Boehringer) . The reaction was left for between 6 and 20 
hours at room temperature.
OIB was made from: 50^1 solution A (1.25M Tris.HCl pH 8.0, 0.125M 
MgCl2 , 25mM /3-mercaptoethanol, O.SmM each of dTTP, dGTP, dATP) , 125^1 
solution B (2M HEPES (4- (2-hydroxyethyl)-l-piperazine- 
ethanesulphoric acid) adjusted to pH 6.6 with NaOH) and 75jul solution 
C (random hexanucleotides OCgo 90 '
Removal of Unincorporated Labelled Nucleotides using Sephadex G-50
A 1ml column of sephadex G-50 was equilibrated in STE (lOmM Tris.HCl 
pH 8.0, 0.15M NaCl, ImM EDIA) by centrifugation at 2,000 x g for 3 
minutes at room temperature. The probe was diluted in 100/il STE and 
added to the column. Unincorporated a-[ 32P]-dCTP was trapped in the 
column and labelled DMA collected after centrifugation at 2,000 x g 
for 5 minutes.
Colony Hybridisation
The method used was essentially that of Grunstein and Hogness (1975) . 
Colonies were blotted on to nitrocellulose filters, which were then 
placed on blotting paper saturated with 0.5M NaOH, 1.5M NaCl, for 2 
minutes. Filters were neutralised by treatment with 0.5M Tris.HCl pH 
7.4, 3M NaCl twice, for 5 minutes. After drying at 37°C, the filters
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were baked under vacuum at 80°C for 90 minutes, and prehybridised for 
60 minutes at 37°C in IX Denhardt's solution, 5 x SSC, 0.3% (w/v) 
SDS, 0.2mg/ml sonicated salmon sperm CNA, 50% (v/v) formamide. 
Hybridisation was performed by incubation under the same conditions 
for between 16 and 20 hours with a sephadex G-50 purified probe 
(108cpm/jug CNA). Filters were washed for 10 minutes in 2 x SSC, 0.1% 
(w/v) SDS at room temperature with shaking; then for 10 minutes in 
0.5X SSC, 0.1% (w/v) SDS. After drying the nitrocellulose filters 
were autoradiographed by exposure to X-ray film (pre-flashed), and 
incubation at -70°C between two intensifying screens.
Agarose Gel Electrophoresis
Agarose gels were made and electrophoresed in 1 x TEE gel buffer. 
The concentration of agarose varied according to the size of DNA 
fragments to be separated, but was typically 0.6 - 1.0% (w/v). 
Generally, agarose gels were cast containing 0.5jLig/ml ethidium 
bromide. Gels were electrophoresed at 7.1V/cm for between 1 and 3 
hours or at 1.4V/cm for to 20 hours. DNA was visualised under short­ 
wave ultraviolet radiation.
Isolation of DMA from Acrarose Gels
The DNA band of interest was cut out of low-gelling point agarose 
(Seakem) and added to an equal volume of 1 x TEE, 0.2M NaCl solution. 
The agarose was melted by incubation at 65°C for 15 minutes; the
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agarose solution was then phenol extracted twice and the DMA 
recovered by ethanol precipitation.
Preparation of Plasmid UNA
Large scale: L-broth (10ml) supplemented by the appropriate 
selecting antibiotic was inoculated with a single colony of the 
plasmid-carrying strain. The culture was grown to stationery phase 
then diluted into 500ml of similarly supplemented L-broth. The cells 
were grown to OD60onm 1 -° at which point chloramphenicol (75mg) was 
added and the culture grown for a further 16 to 20 hours. Cells were 
harvested by centrifugation at 4,000 x g, 4°C for 15 minutes then 
resuspended in 6ml of sucrose mix (50mM Tris.HCl pH 8.1, 40mM EDIA, 
25% (w/v) sucrose). Lysozyme (1ml of lOmg/ml (Sigma)) and 0.5M EDTA 
(0.5ml) were added, the cell suspension was then mixed gently and 
left on ice for 5 minutes. At this point 13ml of Triton mix (50mM 
Tris.HCl pH 8.1, 63mM EDTA, 0.1% (w/v) Triton X-100) was added, the 
cells mixed by swirling and left on ice for 10 minutes. The lysate 
was cleared by centrifugation at 27,000 x g, 4°C for 30 minutes. 
Caesium chloride was added to the cleared lysate to a concentration 
of 0.95g/ml and ethidium bromide to that of Img/ml. Supercoiled 
plasmid DMA was separated from chromosomal and nicked plasmid UNA by 
isopycnic ultracentrifugation at 38,000rpm, 20°C in a Sorvall TV865 
rotor for 16 hours. DMA bands were visualised under short-wave UV 
illumination and the lower supercoiled plasmid removed. Ethidium 
bromide was removed by 4 rounds of extraction with dH20 saturated
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butan-1-ol, and the CsCl by dialysing against TE. DMA was recovered 
by ethanol precipitation.
Small Scale (Mini-Plasmid Preparation)
The method used was essentially that of Birnboim and Doly (1979). 
Cells from 1.5ml of a stationery phase culture, grown in the presence 
of a selecting antibiotic, were pelleted by centrifugation at 17,000 
x g, room temperature for 5 minutes and resuspended in O.lml 34mM 
Tris.HCl pH 8.0, lOmM EDTA, 1% (w/v) glucose solution, then incubated 
at room temperature for 5 minutes. After this, 0.2ml of 0.2M NaOH, 
1% (w/v) SDS (prepared fresh) was added, mixed gently by inversion 
and placed on ice for 5 minutes. Upon the addition of 0.15ml ice- 
cold 5M potassium acetate pH 4.8 and incubation on ice for 5 minutes, 
protein, SDS, and ciiromosomal DMA were precipitated. The precipitate 
was clarified by centrifugation at 17,000 x g, room temperature for 
10 minutes, and plasmid DMA recovered from the salt solution by 
ethanol precipitation. When DMA derived from mini-plasmid 
preparations was digested with restriction endonucleases, PNase H 
(IU) (Boehringer) was included in the reaction to remove RNA prior to 
agarose gel electrophoresis and visualization of DNA.
Preparation of M13 RF DNA
A single fresh plaque of M13 was picked into 2ml of NM522 or TG1 
cells at OD60onm °* 2 and sh^611 for 6 hours at 37°C; then 0.5ml of 
these infected cells was added to 500ml of L-broth along with 5ml of
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cells at OD60onm °- 2 and shaken at 37°C for 7 hours. Cells were 
harvested by centrifugation at 14,000 x g at 4°C. From this point 
onwards the procedure was that of a standard large scale plasmid 
preparation.
2.2.2 Didegxv-nucleotide ENA sequencina methods
Preparation of single-stranded M13 template
Small scale
A fresh single plaque of M13 was picked into 1.5ml of 2 x TY medium 
along with 15jul of a stationery phase culture of TG1 or NM522 cells. 
The culture was shaken vigorously for 5.5 hours at 37°C, then the 
cells were pelleted by centrifugation at 17,000 x g, room 
temperature, for 5 minutes. Fhage were precipitated from the 
supernatant by the addition of 0.2ml 2.5M NaCl, 20% (w/v) PEG 6000 
solution. The mixture was incubated at room temperature for 30 
minutes then centrifuged at 17,000 x g, room temperature, for 10 
minutes, and supernatant removed by vacuum aspiration. The PEG 
pellet was then re-centrifuged and residual supernatant removed. 
Precipitated phage was resuspended in O.lml SETE then mixed by 
vortexing for 10 seconds with SOjLtl phenol. The mixture was 
incubated at room temperature for 10 minutes then centrifuged at 
17,000 x g, room temperature for 2 minutes. Phage ENA was then 
recovered from the aqueous layer by ethanol precipitation.
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Large scale
TG1 cells (SOjul) from a stationery phase culture grown in 2 x TY were 
added to 20ml of 2 x TY and grown for 3 hours at 37°C. This culture 
(100/Ltl) was then used to inoculate 1ml 2 x TY medium along with a 
fresh M13 plaque. Incubation at 37 °C for 4 hours with shaking 
followed, after which cells were pelleted by centrifugation at 17,000 
x g, room temperature for 5 minutes and removed. Phage supernatant 
(1ml) was then used to inoculate a 100ml 2 x TY culture of TC1 cells 
(OD550nm °' 3 )' 1he culture was grown for 4 hours with shaking, at 
37°C then centrifuged at 5,000 x g for 30 minutes at 4°C. The 
supernatant was carefully removed then mixed thoroughly with 0.2 
volume of 2.5M NaCl, 20% (w/v) PEG 6000 and incubated at 4°C for 1 
hour. Phage precipitate was removed by centrifugation at 5,000 x g 
for 20 minutes at 4°C, the supernatant removed and any residue 
eliminated by re-centrifugation of the PEG pellet. The viral pellet 
was resuspended in 0.5ml TE and centrifuged at 17,000 x g for 5 
minutes at room temperature to remove any remaining cells. PEG/NaCl 
solution (0.2ml) was then added to the supernatant, mixed well, then 
incubated at room temperature for 15 minutes or overnight at 4°C. 
The viral pellet was then recovered by centrifugation at 17,000 x g 
as before and any residual supernatant was removed by centrifugation. 
Phenol (0.2ml) was added to the viral pellet suspension (0.5ml) and 
mixed by vortexing for 10 seconds then incubated at room temperature 
for 15 minutes. Following centrifugation for 3 minutes at 17,000 x 
g, room temperature, the aqueous layer was removed and subjected to 
phenol extraction, performed in the same way as before. Single-
stranded DNA was recovered by ethanol precipitation and resuspended 
in TE to a concentration of l^g/ml.
Dideoxv-nucleotide DNA sequencing reactions
The method used was essentially that of Sanger et al. (1977). 
Template ENA was primed by incubating with a 17mer oligonucleotide of 
complementary sequence to that of the cloned insert fragment or lacZ 
gene of M13 mp8, at 80°C for 5 minutes as in section 2.1.5. The 
primer mix was then cooled over a period of 20 minutes to room 
temperature.
Siliconised microtitre plates were used to perform the sequencing 

























Termination mixes (2/^1) were placed in the siliconised wells along 
with primer/template mix (2jnl). After the two solutions were mixed 
by tapping the plate, KLenow mix (2p.I) was added to every well, mixed
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and incubated at room temperature for 25 minutes. Chase mix 
was added and mixed, and the solution incubated for a further 25 
minutes. For single track-sequencing only one termination mix was 
added to primer/template mix, and the rest of the reactions 
performed as normal. For extended CNA sequencing, the template- 
primer reaction was performed as above then 2/xl 1 x Extension mix, 
was added as well as KLenow mix. The extension reaction was 
incubated for 5-15 minutes at room temperature at which point the 
termination mixed (2/il) were added and incubated as normal. The 
chase reaction was not performed.
Urea-polvacrvlamide electrophoresis of sequencing reaction products
Reactions were stopped by the addition of 2^1 of formamide dye then 
incubated at 80 or 100°C for 5 minutes. Sequencing gel mix, prepared 
as in section 2.1.5, was poured into a glass gel former sealed by 
adhesive tape (40 x 20 x 0.035cm). A suitable comb was then 
inserted; either a Flat former comb enabling the subsequent use of a 
"shark's tooth" comb (BRL) or a square-toothed sequencing gel comb. 
The polymerised gel was assembled into an electrophoresis kit and the 
upper and lower tanks filled with 1 x TBE. The reaction mixes were 
loaded using drawn out glass capillaries in a G-A-T-C order.
The samples were electrophoresed at 50V/cm for at least 2 hours, and 
gels fixed in 10% (v/v) acetic acid, 10% (v/v) methanol for 10 
minutes, then dried on 3MM paper using a vacuum gel drier (Zabona).
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The gel was then autoradiographed for between 16 and 20 hours at room 
temperature using X-ray film.
2.2.3 Site-directed mutaaenesis methods
Phosphorvlation of 5' ends of CNA with T4 DMA Dolvnucleotide kinase
Polynucleotide kinase (PK) was used to add 5 1 phosphate groups to 
unphosphorylated 17mer oligonucleotides which were then used in SCM 
reactions, Approximately 100pm of oligonucleotide was incubated in 1 
x PK buffer (section 2.1.4) with 1U of T4 CNA polynucleotide kinase 
(Boehringer) at 37 °C for 30 minutes. The substrate providing 
phosphate was ATP at 20mM. The reaction was stopped by incubation 
at 70 °C for 10 minutes and rapid cooling on ice.
Labelling 5 1 ends of oligonucleotides with ?f ~[ 32P]-ATP using T4 DMA 
poly-nucleotide kinase
Adenosine 5'-2f-[ 32P] Triphosphate (Amersham, 3000 Ci/mMol, 30/iCi) 
was used to label 15pm of oligonucleotide in the presence of 1 x PK 
buffer with 1U of PK (Boehringer) at 37 °C for 30 minutes.
Screening M13 plaques by hybridisation with mutagenic oliqonucleotide
The method used was essentially that of Zoller and Smith (1983) . 
Plaques arranged in asymmetric grids of a hundred were blotted on to 
nitrocellulose filters. The filters were then transferred to a sheet
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of blotting paper saturated with 0.5M NaOH and left for 3 minutes at 
room temperature. They were neutralised by transferring to 1M 
Tris.HCl pH 7.4 soaked paper (twice for 1 minute each), then to 0.5M 
Tris.HCl pH 7.5, 1.5M NaCl soaked paper (5 minutes). The blotted 
plaques were dried at room temperature for 20 minutes then baked for 
60 minutes at 80°C in a vacuum oven. Filters were pre-wetted in 6 x 
SSC and prehybridised at 67°C for 5 minutes in 10 x Denhardt's, 6 x 
SSC, 0.2% (w/v) SDS solution. After rinsing in 6 x SSC each filter 
was dropped in probe solution ( 32P labelled oligonucleotide 7.0 x 
109cpm/Mg/ diluted in 4ml 6 x SSC), and left at room temperature for 
60 minutes.
Filters were initially washed at room temperature in 6 x SSC (3 x 
30ml, one minute washes per filter), partially dried then 
autoradiographed using pre-flashed X-ray film at -70 °C for 1 to 3 
hours. The filters were then re-washed in 6 x SSC at a temperature 
5°C below that of the calculated Tm (Wallace et al., 1979) for the 
mutant oligonucleotide-template duplex, then autoradiographed. The 
washing and autoradiographing process was repeated in 6 x SSC at a 
temperature corresponding to the Tm.
Gapped-Duplex Mediated Site-Directed Mutagenesis
The method used was that of Kramer et al. (1984a). The Gapped-Duplex 
was formed by adding O.lpm (0.5/zg) M13 mp8 RF DNA cut with BamHI to 
0.5pm (1.25/ig) template DNA in 30^1 12.5mM Tris.HCl pH 7.5, 0.2M KC1, 
then heating to 65 °C for 1 minute and cooling to room temperature
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over 20 minutes. The template-RF mixture (8/il) was then added to 
7.5pm (35ng) of 5 1 phosphorylated mutant oligonucleotide in a final 
volume of lO^tl, heated to 65 °C for 3 minutes then cooled at room 
temperature for 20 minutes. The primed-Gapped-Duplex was "filled-in" 
by incubation at room temperature for 45 minutes with T4 DMA ligase 
(2U, Boehringer), E. coli ENA polymerase I KLencw fragment (1U, 
Boehringer) in the presence of 20mM Tris.HCl pH 7.5, 15mM MgCl2/ 
12.5mM KC1, 2mM DTT, 124/jM ATP, 125/LtM dNTPs. Competent EMH71-18 
mutL cells were transformed with the reaction mix and plated on 
minimal media with EMH71-18 cells.
Thio-deoxv C mediated site-directed mutagenesis
The method used was based on the procedure developed by Taylor et al. 
(1985 a, b). Mutant oligonucleotide (5 1 phosphorylated; 8pm, 40ng) 
was annealed to single-stranded template DMA (3.8pm, 10/jg) by 
incubation in 0.15M Tris.HCl pHS.O, 0.15M NaCl (34/xl) at 70°C for 3 
minutes followed by slow cooling at 37°C for 30 minutes then cooling 
on ice. Extension and ligation of mutant strand DMA was performed by 
the incubation of template-primer duplex at 16°C for 15 hours with E. 
coli DMA polymerase I KLenow fragment (12U, Amersham), T4 DMA ligase 
(12U, Amersham), lOmM MgCl2 , 1*M ATP, 0.5mM dATP, O.SmM dGTP, 0.5mM 
dTTP and O.SmM dCTP-a-S (Sp isomer). The reaction mixture was 
diluted to 0.27ml with NaCl to a concentration of 0.6M and passed 
through two 13mm Sartorius nitrocellulose filters (SM11336) in a 
Swinnex Millipore filtration device (SX001300). The dsDNA contained 
in the filtrate was recovered by ethanol precipitation and
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resuspended in lOmM Tris.HCl pH 8.0, 50mM NaCl, 20/M EDIA. A fifth 
of the ENA recovered (about 3/ig) was digested with Ncil restriction 
endonuclease (5U, Amersham) in 15mM Tris.HCl pH 8.0, 20mM NaCl, lOmM 
MgCl2 , 30/iM EDTA, 15mM DOT. To this digest, E. coli Exonuclease III 
(SOU, Amersham) was added and incubated at 37°C for 30 minutes in 
55mM Tris.HCl pH 8.0, 67mM NaCl, lOmM MgCl2 , O.lmM EDTA, 15mM DTT. 
Both enzymes were then inactivated by incubation at 70 °C for 15
minutes, and the partial duplex repolymerised and ligated using E..
» 
coli DNA polymerase I (3U, Amersham) and T4 DMA ligase (2U, Amersham)
in 50mM Tris.HCl pH 8.0, 60mM NaCl, lOmM MgCl2 , 60jUM ATP and 40/uM 
dNTPs at 16°C for 3 hours. Competent TG1 cells were transformed with 
the reaction mix and plated on minimal medium with TG1 cells.
2.2.4 Protein and immunological methods 
Protein extraction from S. cerevisiae
The method used was developed from that of Murray et al. (1984). 
Cultures of DBY746 LELT1" cells (11.) were grown to OD600nm 2.0 in low 
phosphate synthetic medium, then cells harvested by centrifugation at 
5,000 x g for 15 minutes at 4°C. Cells were washed with PBS (100ml) 
then resuspended in PBS containing 1% (w/v) Triton X-100, O.lmM 
phenylmethyl sulphonyl fluoride (FMSF) (10ml). Acid-washed 
(Ballitoni No. 1) glass beads (14g) were added to the suspension in 
glass tubes, then agitated by vortex mixing 10 times for 30 seconds, 
with one minute incubations on ice between each mixing. The lysate
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was clarified by centrifugation at 12,000 x g for 10 minutes at 4°C 
and the supernatant stored at -70°C.
Batch Fermentation
Cultures grown in high phosphate synthetic medium (1.851.) were 
diluted into 501. of low phosphate medium and incubated for 
approximately 20 hours at 30 °C in a Fermatic 50 LB (Biotec) batch 
fermenter until ODgQOnm 2 -° was achieved. A cell pellet was 
recovered (-lOOg) by continuous-flow centrifugation, washed with PBS, 
then resuspended in 1/250 volume with PBS containing 1% (w/v) Triton 
X-100 and O.lmM FMSF. The cells were broken by 3 x 15 second 
passages through a French press (700kg/cm3 ) and extract clarified by 
centrifugation at 17,000 x g for 10 minutes at 4°C. Ammonium 
sulphate precipitation were performed by adding a pre-weighed amount 
over a period of 30 minutes to crude extract at 4°C with constant 
mixing. The precipitate was incubated for a further 30 minutes then 
centrifuged at 17,000 x g for 10 minutes at 4°C and the pellet 
resuspended in PBS. Dialysis for a period of between 16 to 20 hours 
against PBS removed any residual ammonium sulphate associated with 
the precipitated protein.
SDS-polyacrvlamide gel electrophoresis (Laemmli, 1970)
Separating gel solution (13% w/v) was prepared as in section 2.1.6, 
and the gel cast between 25 x 20 x O.lcm glass plates, then overlaid 
with dH2O, after polymerisation stacking gel was poured and the comb
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inserted. The gel was assembled into a vertical gel kit and samples 
boiled for 5 minutes in IX loading buffer before loading. Electro- 
phoresis in IX buffer at 4.5V/on was carried out for 6 hours at room 
temperature.
Immunoblotting
The method used was largely based on that of Towbin et al. (1979). 
The nitrocellulose and SDS-polyacrylamide gel were sandwiched 
together between 6 pieces of blotting paper (of similar size) which 
were pre-wetted in transfer buffer. The sandwich was placed in the 
"Trans-blot" apparatus (Biorad), filled with transfer buffer, and 
protein transferred at 2.TV/cm for 16 hours or 8V/cm for 4 hours at 
4°C. The filter was stained in 0.5% (w/v) Ponceau S solution for 30 
seconds and destained in df^O, to check the efficiency of transfer 
of protein, then incubated at room temperature in 5% (w/v) milk 
powder, 0.5% (v/v) NP40, 0.1% (w/v) sodium azide, 1 x TS solution for 
a period of 4 to 10 hours. After blocking, antibody was added in the 
same solution and the filter incubated, with shaking, for 16 to 20 
hours at room temperature. The filter was then washed 6 times over a 
period of 30 minutes in 1 x TS then incubated with a 1:7500 dilution 
of goat anti-rabbit IgG (Fc) alkaline phosphatase conjugate (Promega 
Biotec) in milk powder buffer, for 3 hours at room temperature. The 
filter was then washed with 1 x TS as before, and the presence of 
bound alkaline .phosphate detected by incubation in 0.1M Tris.HCl pH 
9.5, 0.1M Nad, 50mM MgCl2/ 0.33mg/ml Nitro-blue-tetrazolium (NET),
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0.25mg/ml 5-bromo-4-chloro-3-indolyl phosphate (BCIP) for 2 to 15 
minutes at room temperature.
Lowrv assay (Lowrv et al.. 1951)
Protein sample (0.4ml) was added to 2% (w/v) Na2OC>3, 0.01% (w/v) 
CuSO4/ 0.02% (w/v) sodium citrate, 0.1M NaOH solution (2ml) mixed 
well and incubated at room temperature for 10 minutes. Folin-Cocateu 
reagent (50% (v/v) in dH20, 0.2ml) was then added, mixed well and 
left to stand at room temperature for 15 minutes. Absorbances at 
OD550nm were then recorded; the assay was calibrated using BSA at 
concentrations of 1 to 100jiig/ml.
Radioiinmunoassay for HBsAg
The procedure used was based on- the Abbott Ausria II kit for the 
detection of HBsAg using antisera raised against human HBsAg. 
Samples diluted in RIP buffer (0.2ml) were placed in the wells of 
microtitre plates along with polystyrene beads coated with guinea pig 
anti-human HBsAg and incubated at room temperature for between 16 and 
20 hours. Samples were then removed by vacuum pump aspiration and 
the beads washed in the wells 10 times with 1ml of dH2O. After this 
[ 125I]-anti-human HBsAg (0.2ml; 0.74/iCi/ml) was added and the beads 
incubated at 45 °C for 1 hour. label was then removed by aspiration 
and the beads washed as before. The degree of gamma-radioactivity 
of each bead was determined using a 1KB 1275 mini-gamma counter.
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Double antibody radioimmuno-precipitation assay (DARIP)
The assay was first used for the detection of HBsAg or anti-HBsAg 
antibodies by Burrell et al. (1978). It was used also as the basis 
of a competition assay determinig the subtypic activity of HBsAg and 
anti-HBsAg sera. The basic assay was as follows:
Antisera was diluted in RIP buffer, then added to 50^1 [ 125I]-HBsAg 
(SOOOcpm in O.Sng HBsAg). A further O.lml of RIP buffer was added, 
mixed well, then the mixture incubated for between 20 and 48 hours at 
4°C. The second antibody, diluted 1:1 in RIP buffer, was then added 
(O.lml), and mixed well. The specificity of the second antiserum was 
directed against the first, so therefore enabled the precipitation of 
complexes between antibodies from the first serum and antigen. The 
mixture was incubated for 16 to 20 hours at 4°C then diluted in 0.1% 
(w/v) starch in RIP buffer (1ml) and centrifuged at 2,500 x g for 10 
minutes at room temperature. The supernatant was decanted and the 
amount of gamma-radioactivity in the pellet determined. The 
relative avidity of the HBsAg antiserum for HBsAg was expressed as 
the percentage of total [ 125I]-HBsAg precipitated.
The relative avidity of HBsAg for anti-d and anti-y monospecific 
antisera was tested using an inhibition DARIP assay. Antigen 
preparation (O.lml, diluted in RIP buffer) was incubated at 37°C for 
2 hours with monospecific antiserum (50/Ltl) • Then labelled HBsAg was 
added (50^1), mixed well, and the mixture incubated for between 20 
and 48 hours at 37 °C. The second, precipitating, antibody was then
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added (0.15ml) the solution mixed well and incubated at 4°C for 16 to 
20 hours. Labelled antigen-antibody complexes were recovered as 
described before and the percentage of total [ 125I]-HBsAg 
precipitated determined. In this procedure the avidity of the 
unlabelled test antigen for monospecific anti-HBsAg serum was 
indicated by the degree of inhibition of reaction between the 
labelled HBsAg (of appropriate subtype) and antiserum.
Preparation of anti-HBsAg sera
The inoculation of mice with yeast produced HBsAg was kindly 
performed by G Leadbetter, Department of Bacteriology, Edinburgh 
University Medical School. Mice (Balb/c) were injected 
intraperitoneally (0.8ml) and intramuscularly (O.lml, with O.lml 
Freund's complete adjuvant) with ammonium sulphate fractions (20- 
35% saturation) of yeast extracts containing about 3/zg HBsAg. After 
6 weeks the animals were boosted with a similar amount of antigen 
applied in the same manner. The third inoculation was performed as 
before 14 days after the second, then after 10 days the animals were 
bled (O.lml removed) and the serum tested for the presence of anti- 
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3. Site-Directed Mutagenesis of the S Gene
In order to investigate the role of specific amino acids in the 
determination of HBsAg djrimurKxiiemistry, the site-directed mutagenesis 
of single-stranded S gene DNA was performed.
3.1 Method of Site-Directed Mutagenesis
The basis of the two methods of SEM used in the project was the 
hybridisation of a single-stranded DNA oligonucleotide (17 bases 
long) to a single-stranded cloned copy of the S gene. The 
oligonucleotide was complementary to the wild type gene sequence 
except for one or two bases, under the hybridisation conditions used 
this mismatch did not disrupt the oligonucleotide:template duplex. 
The oligonucleotide then served as a primer for extension of the 
template sequence by the copying of the opposite DNA strand by E.. 
coli DNA polymerase I KLenow fragment and T4 DNA ligase resulting in 
a heteroduplex of mutant and wild type DNA. ^Depending on the method 
used, this basic process can be optimised to varying degrees so as to 
increase the production of mutant single-stranded M13 DNA.
The two methods of SEM used in the project were the Gapped-Duplex 
method (Kramer et al., 1984a; figure 3.1.1A) and the Thio-<aeoxy C 
method (Taylor et_al., 1985a, b; figure 3.1.IB). The former method 
optimised the formation of mutant-template duplexes by allowing 
Gapped-Duplexes to form between single-stranded template and 
denatured RF M13 molecules. The latter method involved DNA synthesis
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template is removed by filtration and the remaining double- 
stranded CNA subjected to Ncil digestion. Ihe enzyme will not 
cut CNA at its recognition site of CC-GG if dCTP-a-S has been 
incorporated in the CNA. Ihe result of this is that Ncil nicks 
only the template strand of the heteroduplex, which is removed 
by subsequent E. coli Exonuclease III digestion. A homoduplex 
of mutant CNA is produced upon repolymerisation with E. coli CNA 





As described in section 2.2.3 (Kramer et al.. 1984a), linearised 
RF M13 DMA is heated with an excess of single stranded M13 DNA 
(containing the target sequence) and mutant oligonucleotide. The 
mixture is cooled slowly and the Gapped-Duplex formed with 
hybridised oligonucleotide in place. Extension takes place from 
the 3'-OH of the RF strand and the 3'-OH of the mutant 
oligonucleotide by the action of E. coli DNA polymerase I KLencw 
fragment and T4 DNA ligase until the synthesised mutant strands 
are ligated to the 5' end of the RF-derived strand and the 5 1 
end of the mutant oligonucleotide. These duplexes are then used 
to transform mismatch repair deficient BMH71-18 mutL cells.
B. Thio-deoxy C method of mutagenesis
As described in section 2.2.3 (Taylor et al., 1985 a and b) 
oligonucleotide (in excess) is annealed to M13 single-stranded 
template containing the sequence to be mutated, by heating and 
slow cooling. The mutant strand of the duplex is extended from 
the primer with E. coli DNA polymerase I KLenow fragment and T4 
DNA ligase where phosphorothioate-modified dCTP is incorporated 
as well as the standard dATP, dTTP and dGTP. Extension is 
continued around the template and the synthesised strand ligated 























































































































































































































































from the hybridised mutant oligonucleotide around a naked template 
and the removal of contaminating un-primed template by filtration, a 
series of biochemical steps were then performed to remove the 
template strand of the hetercduplex and leave a homcduplex of mutant 
DMA.
3.2 Sub-Cloning of the S Gene contained in theBamHI Fragment of 
PHIN/ G-2
The plasmid pHIN/G-2 (5/ig) was digested with BamHI (10U) and the 
1.78kb fragment which contained the HBV S gene and S. cerevisiae FHO5 
gene promoter (figure 3.2.1) separated from the 8.67kb fragment by 
agarose gel electrophoresis. Ihe 1.78kb fragment was recovered from 
the low melting point agarose and resuspended in TE to a final 
concentration of approximately O.Ipg. The RF form of M13 mp8 (l^g) 
was similarly digested with BamHI. then phenol extracted and ethanol 
precipitated and resuspended in TE to a final concentration of 
0.1/zg. The BamHI digested M13 mp8 DMA (O.ljiig) was ligated with the 
pHIN/G-2 1.78kb BamHI fragment (O.ljug) using T4 CNA ligase (1U) 
(figure 3.2.2). The ligation mix was then used to transform NM522 
cells along with the following control samples; digested unligated 
M13 mp8 DMA (O.l^g), self ligated digested M13 mp8 DMA (0.1/jg) and 
supercoiled M13 mp8 DNA (Ing). Typically, using the CaCl2 method of 
transformation about 103 plaques per ng of supercoiled M13 DNA were 
observed. Plaques derived from recombinant clones of M13 mp8 DNA 
were distinguished from other transformants by Xgal/IPTG colour 
selection with the white plaques containing Lac~ M13 mp8 recombinant
104
Figure 3.2.1 Structure of pHIN/G-2
The S. cerevisiae/E. coli shuttle vector pHIN/G-2 (Murray et al., 
1984) contains the 2jLt origin of replication from S. cerevisiae and 
the pAT153 derived Col El origin of replication. Selection in S.. 
cerevisiae is afforded either by the IEU2 gene or by the Tn903 
encoded G418R gene. The pAT153 region also contains the /3-lactamase 
gene which confers the AMP** phenotype on transformed E. coli cells. 
Expression of HBsAg is achieved by the in—frame fusion of the yeast 
acid phosphatase gene(FHOS) promoter to an Aval site 27bp upstream 
of the start of the S gene. Transcription from the promoter is 
repressed by phosphate (Schurr and Yagil, 1971) and S gene 
transcription terminated by the FH05 terminator. The FH05 promoter, 
the whole of the S gene, and approximately 0.5kb of HBV DMA is 
contained in the 1.78kb BamHI fragment.
Also indicated are the sites mutated in the S gene (denoted by 
stalked diamonds) and the positions of sequencing primers (denoted by 
stalked circles). The approximate areas sequenced from each primer 





















































































































































































clones and the blue Lac*" non-recombinant clones. Recombinant clones 
were then used to make single-stranded template with NM522, which was 
then sequenced to determine which clones contained the BamHI fragment 
in the orientation indicated in figure 3.2.2.
3.3 Gapped-Duplex Catagenesis
The Gapped-Duplex method of SDM (figure 3.1.1A) was used to make the 
d/y set of mutants of the pHIN/G-2 S gene. The oligonucleotides used 
were all 17mers and kindly synthesised by Biogen Inc. The 
designation of name, oligonucleotide and nucleotide position 
associated with each mutation is shown in figure 3.3.1.
The adwl (nucleotide position 1775), adw2 (nucleotide position 1799), 
and adw3 (nucleotide position 1835) mutants were the first mutants to 
be made using the SEM protocol of section 2.2.3, using oligo­ 
nucleotides phosphorylated by T4 DNA polynucleotide kinase. The SCM 
reactions were performed on template DNA (0.1/jg) prepared from 1.5ml 
cultures of M13 mp8.pHIN/G~2 BamHI phase infected NM522 cells. 
Several control SDM annealings/reactions were carried out alongside 
the reaction proper. They were: I template + oligonucleotide, II 
template + RF, III template, IV RF. These control mixes and the 
reaction proper mix were used to transform competent BMH 71-18 mutL 
cells. The "mutL" cells were used for this experiment since they 
apparently increased the efficiency of SDM by being deficient in the 
ability to correct aberrant DNA duplexes such as the ones produced by 
the Gapped-Duplex method (Kramer et al.. 1984b). Typical numbers of
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Figure 3.3.1 Oligonucleotides used for site-directed imitagenesis
All oligomers (IVmers) were synthesised by a solid-phase 
phosphodiester procedure by Biogen Inc (adw IVmers) or Department of 
Chemistry, University of Edinburgh (a-region 17mers and internal 
sequencing primers) . The designation of name to oligonucleotide was
as follows: adwl - 1775T ~" A (ser -> thr) , adw2 - 1799G ~* A (arg -*
A -* T cc -*• m lys), adw3 - 1835^ x (tyr -> phe) , al - 1860/1861 (pro -*
("Y"1 _>. AT1 T" -* A
gly) , a2 - 1860/1861 ^ (pro -* ile) , a3 - 1806 (cys -* ser) , 
a4 - 1878T " A (cys -* ser) .
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adwl 5 ' T C C A G G A|A CAlTCAACCA 3 '
Thr 113
adw2 5 ' A C C C T G C|A A A|A C C T G C A 3 '
Lys 122
adw3 5 ' C T C T A T G|T T T|C C C T C C T 3 '
Phe 134
C C
al 5 ' T A C A A A A|G G T|T C G G A T G 3 '
Gly 142
C C 
a2 5 ' T A C A A A A|A T T|T C G G A T G 3 '
He 142
a3 C A G A A C ClA G C|A C G A C
Ser 124
a4 51 T G G A A A ClA G ClA C C T G T A 3 '
Ser 147 
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transformants from successful SCM reactions of this type (i.e. 5% of 
transformants were mutants) were as follows: I template + 
oligonucleotide-656, II template + RF-176, III template-2, IV RF-42, 
V (Reaction Proper) template - oligonucleotide + RF-816 (figures from 
adw2 SEM experiment). The controls allowed the monitoring of 
components of the SCM system; if the background number of 
transformants from template (III) or RF (IV) rose significantly, then 
screening was aborted and the reactions re-performed with new DNA. 
The level of transformants from II (RF + template) indicated the 
efficiency of the "filling in" reaction, since duplexes made were 
primed from the 3'-OH of the cut RF strand and continued to the 5'-P 
of the RF strand of the Gapped-Duplex. The efficiency of 
oligonucleotide hybridisation and priming was indicated by the level 
of template (I) transformants. The plating cells for the 
transformation of EMH71-18 mutL cells by SCM reaction mixes were 
EMH71-18, which were used for all further experiments with the mutant 
phage.
Initial screening for adwl, adw2 and adw3 mutants was performed by 
differential hybridisation with the original mutagenic 
oligonucleotide (Zoller and Smith, 1983; section 2.2.3). The Tm 
value for each duplex between oligomer and target sequence was 
determined using the Wallace rule (Wallace et al., 1979). The Tm 
values were determined as: adwl 52°C, adw2 50°C, adw3 50C°. By 
washing at 22°C, Tm - 5°C and Tm, in 6 x SSC, the necessary 
discrimination between unmutated and mutated sequence was achieved 
(figure 3.3.2). The observed frequency of occurrence of mutant
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Figure 3.3.2 Use of differential hybridisation to identify a
mutant sequence
Oligonucleotide (adw2) was labelled with #-£32P]-ATP using T4 DNA 
polynucleotide kinase and hybridised to DNA from M13 phage 
immobilised on nitrocellulose according to the procedure described in 
section 2.2.3. The filter was washed at 45°C (Tin - 5°C) in 6 x SSC 
(A). Upon increasing the temperature of the wash to 50 °C (Tin) the 
necessary discrimination between unrnutated and adw2 mutated sequence 
was achieved (B). The plaques indicated by arrows contained adw2
t
mutated sequence, as judged by the relative stability of oligomer-CNA 
duplexes at the Tin.
The Wallace r^Le states (Wallace et al., 1979): The melting 
temperature (Tm), defined as the temperature when half the duplex 
molecules have disassociated into their constituent strands, can be 
determined by the formula:
Tin (°C) =4 (G + C) +2 (A + T)
where G, C, A and T indicate the number of the corresponding 
nucleotides in the oligomer. The formula applies for DNA oligomers 






clones was 2-6% for all transformants. Candidate mutant phage were 
then plaque purified from the KTB stock (one plaque diluted in SOjUl), 
single-stranded template CNA prepared and then sequenced; mutant 
clones were stored at -20°C.
The sequences of the mutated sites in adwl, adw2 and adw3 mutants are 
presented in figure 3.3.3.
The investigation of the effect of combinations of adw mutants was 
initiated by taking template mutated at a single position and 
mutating with a different adw oligonucleotide. Thus, by mutating an 
adw2 template with adwl oligonucleotide the adw2.1 mutant was 
produced. Similarly, adw3.1 was created by mutating an adw3 template 
with adwl oligonucleotide and by using the adw3 oligonucleotide on 
the adw2.1 template, adw2.1.3 was produced. The screening procedure 
used in these mutagenesis experiments involved the single-dideoxy 
nucleotide sequencing of 60 template preparations from original SEM 
transformants. A sequence for just one nucleotide (usually A) was 
produced, and the desired substitution easily recognised (figure 
3.3.4). Candidate mutant templates were then used to transform 
EMH71-18 and the resulting plaques used to make template CNA. Fully 
sequenced mutant template was stored at -20°C (figures 3.3.5 and 
3.3.6).
115
Figure 3.3.3 Nucleotide sequence of S genes mutated singly at the
adwl, adw2, and adw3 sites
The sequence of the mutated DNA was determined by performing dideoxy 
chain terminator reactions (Sanger et al., 1977) which were resolved 
on 6% (w/v) urea-polyacrylamide gels (section 2.2.2).
The nucleotide position where wild type (wt) nucleotide was 



















































G A T C
adw3
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Figure 3.3.4 Single dideoxy nucleotide screening for mutants
A. T° screen of 8 single-stranded CNA preparations from phage 
produced after thio-deoxy C mutagenesis of S gene by a4
oligomer (section 3.4). The desired nucleotide substitution
T -»• A 
1878 was present in 7/8 templates sequenced (filled
diamonds) and was inferred by the loss of the T at position 
1878.
B. A° screen of 16 single-stranded DNA preparations from phage 
produced after Gapped-Duplex mutagenesis of adw2 S gene by adwl
oligonucleotide (section 3.3). The desired nucleotide
T -*• A 
substitution 1775 was present in 1/16 templates sequenced
(filled diamonds) and was inferred by the appearance of an 
extra A band at 1775. The extra A nucleotide present at 1799 









Figure 3.3.5 Nucleotide sequence of S genes harbouring double adw
mutations
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G A T C
wt
1775








Fiqure 3.3.6 Nucleotide sequence of S gene harbouring the triple
adw mutation










































G A T C
I
1775













3.4 Thio-deoxv C mediated Site-Directed Mutaqenesis
The imitations of the S gene, at nucleotides coding for the a-region, 
were made using the thio-deoxy C method (figure 3.1.IB). The 
oligonucleotides used were all 17mers and were obtained from the same 
source as the 'adw 1 oligonucleotides. The designation of name to 
each oligonucleotide in reference to the position mutated is shown 
in figure 3.3.1.
The mutants al, a2, a3 and a4 were made using the SDM protocol of 
section 2.2.3 with oligonucleotides phorphorylated by T4 DNA 
polynucleotide kinase.
The template DNA used was prepared from 100ml cultures of TG1 cells 
infected with M13 mp8.pHIN/G-2 BamHI phage (section 2.2.3). The 
reactions were monitored by observing the mobility of DNA 
intermediates subjected to agarose gel electrophoresis (figure
3.4.2), and the final reaction mix used to transform CaCl2 competent 
TG1 cells. This strain was used because cells exhibited higher 
transformation efficiencies with hemithiolated DNA duplexes than did 
equivalent cells such as NM522 (Taylor et al., 1985a). The 
resulting plaques were screened for the presence of mutated S gene by 
the single dideoxy-nucleotide sequencing of twenty individual 
template preparations (figure 3.3.4). Typical mutation efficiencies 
observed were between 65 and 90% of total phage. Candidate mutant 








Photograph of 1% (w/v) agarose gel showing products of thio-deoxy C 
SCM. Sample 1 - 200ng double-stranded RF DNA; Sample 2 - 200ng 
single-stranded DMA template; Sample 3 - DNA after repolymerisation; 
Sample 4 - DMA after exonuclease III digestion (note presence of 
partially single-stranded DNA); Sample 5 - DNA after filtration and 
nicking (note absence of single-stranded DNA and large amount of 
nicked DNA) ; Sample 6 - DNA after extension and ligation.
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Figure 3.4.3 Nucleotide sequences of S genes mutated at the al, a2,
a3 and a4 sites
The sequencing of mutated DMA was as described in figure 3.3.3.
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1806 T
Q A T C
Wt
G A T C
wt
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3.5 Sequencing of Mutated S Genes
It has been observed that during SEM of certain sequences spurious 
mutations arise in the template sequence caused by the aberrant 
hybridisation of oligonucleotides or by other features of the 
protocol used (Zoller and Smith, 1983). Furthermore, the use of the 
EMH71-18 mutL cells in the 'adw' mutagenesis experiments could 
conceivably have contributed to the occurrence of undesirable 
mutations. Before any SEM was attempted, the sequences of the 
oligonucleotides were checked against that of the S gene to ensure 
that the only region of the gene homologous was the region either 
side of the nucleotide to be mutated. This check was performed using 
the University of Wisconsin Genetics Computer Group (UWGCG) 
"wordsearch" program, and indicated that no cryptic regions of 
homology existed between the oligonucleotides and the S gene.
Upon the production of the desired mutant, the sequencing of the S 
gene from each was undertaken. Initially sequencing from the primer 
HBV-1 (1704) was performed to establish that a mutation had been 
made, the area sequenced was from about 1710 to 1950 (figure 3.2.1). 
Using extended dideoxy-nucleotide sequencing and resolution of 
reaction products by urea-polyacrylamide electrophoresis (50V/cm for 
about 6 hours) (section 2.2.2), it was possible to sequence the 3' 
end of the S gene at 2114 from the HBV-1 primer. The 5' section of 
the gene was sequenced from the HBV-2 17roer primer (1417) using 
standard dideoxy-nucleotide sequencing up to approximately position
128
1730. The full sequence of the S genes from all 10 mutants revealed 
no undesirable mutations.
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4. EXPRESSION OF HBsAq IN S. CEREVISIAE
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4. Expression of HBsAa in S.
In order to assess the phenotypic triplications of the 'adw 1 and a 
group mutations made in section 3, it was necessary to clone and 
express the mutant S genes in yeast. This was done using the E. 
coli/ S. cerevisiae shuttle vector pHIN/G-2 (figure 3.2.1; Mjrray et 
al., 1984) to express the mutant genes in cells from the appropriate 
S. cerevisiae strain.
4.1 Sub-Cloning Mutant S Gene into pHIN/G-2
Sequenced mutant template (lOng) was used to transform TG1 or NM522 
cells and the resulting plaques used to prepare RF DMA (section 
2.2.1) to a final concentration of 0.1/^g. Resulting RF M13 DMA 
(5^g) was digested with BamHI (10U) as was pHIN/G-2 DNA (5/zg) which 
contained the original 1.78kb BamHI insert (figure 4.1.1). Both 
digests were subjected to agarose gel electrophoresis; the 1.78kb 
fragment from the M13 clone and the 8.67kb fragment from pHIN/G-2 
were then purified from low melting point agarose and resuspended at 
a concentration of 0.1/^g in IE. Using T4 DNA ligase (1U) the two 
BamHI fragments were ligated together (0.25^ 1.78kb fragment, O.ljug 
8.67kb fragment) and used to transform CaCl2 competent HB101 cells. 
Selection for transformants was afforded by plating on L-amp plates 
(100/Ltg/ml) and recombinants detected by colony hybridisation (section 
2.2.1) of nitrocellulose-iinmobilised colonies with pHIN/G-2 1.78kb 
BamHI probe (108cpm/Mg) prepared by rardom-prinied, polymerase 
reactions (section 2.2.1). In order to establish that contaminatirKg
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1.78kb fragment, from original pHJN/G-2, did not co-purify with the 
extracted 8.67kb fragment used for cloning the mutant fragments, 
colonies from self-ligated 8.67kb DNA were screened alongside those 
derived from every mutant fragment ligation. None of these colonies 
gave a positive signal in hybridisation experiments; whereas the 
typical frequency of occurrence of positive colonies from ligations 
involving isolated mutant fragments was between 10% and 20% of total 
colonies. Hybridisation-positive colonies were analysed for the 
orientation of the BamHI insert by digestion of mini-preparation, 
plasmid DNA with Clal (figure 4.1.1) followed by agarose gel 
electrophoresis (figure 4.1.2). The correct pHIN/G-2 recombinant 
plasmids were then produced from 500ml L-broth cultures (containing 
ampicillin at 100/Ltg/ml), and stored at a final concentration of 
1/ig/ml.
4.2 Expression of HBsAg in Yeast
Spheroplasts of the yeast cells DBY746 (LEU~) were prepared, then 
transformed with pHIN/G-2 plasmid DNA (LEU*) and plated in 3% (w/v) 
agar on leucine deficient minimal plates. Transformation 
efficiencies were about 1 x 102/jLig. Yeast cells were grown in 
ininiinal synthetic medium (section 2.1.2; Schurr and Yagil, 1971) 
containing lg/1. KH2P04 , to an OD6o0nm of about 2 -°> then diluted 
into low phosphate medium (30mg KH2P04/1.) and grown again to OD600nm 
2.0 inducing HBsAg production by derepressing transcription from the 
PHO5 promoter. Preparation of extracts from cells of 11. cultures 











Separation of Clal digest products from inini-plasmid preparations of 
pHIN/G-2 BamHI recombinants, by electrophoresis through 1% (w/v) 
agarose. Depending on the orientation of the 1.78kb BairHI fragment, 
the sizes of Clal generated fragments were: 1.2kb, 4.1kb, 5.0kb or 
2.5kb, 2.7kb, 5.1kb. The former set of Clal fragments indicated the 
desired orientation of BamHI insert in pKEN/G-2.
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protein extracts were prepared from 11. cultures of all the pHIN/G-2 
'adw 1 mutants as well as from the unmutated strain. The level of 
antigen was estimated using the Abbott Ausria II radioimmunoassay 
system for detection of human HBsAg. The system was calibrated for 
use with yeast derived HBsAg, by testing with 99% pure pHIN/G-2 
derived HBsAg (a gift from the Green Cross Corporation). The level 
of HBsAg present in the extracts was about 50ng/mg protein (about 
0.05% total cell protein).
Estimation of expression levels for pHIN/G-2 clones of mutants in the 
a-region could not be performed by the Ausria II system since antigen 
produced may have had impaired reactivity in the HBsAg detection 
system. To estimate the amount of HBsAg produced in 501. 
fermentations of cells harbouring unmutated, 'adw 1 and a-region 
mutated S genes (section 2.2.4), a Western blot experiment was 
performed. An IgG preparation of a rabbit antiserum (NRA/BC-4B) was 
used in the experiment (section 2.1.7). The antiserum was raised 
against SDS treated, reduced HBsAg produced from pHIN/G-2 transformed 
yeast. The antiserum was considered as having anti-denatured HBsAg 
specificity, therefore in the experiment detection of HBsAg was not 
affected by any antigenic property of the native protein (figure 
4.2.1).
Using this approach the level of denatured HBsAg present in ammonium 
sulphate fractions (20 - 35% saturation) of protein from cells 
containing S genes mutated in the a-region (al - a4), at positions 
122arg "* lyS (adw2), 134tyr ~* phe (adw3) and wild type were
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Figure 4.2.1 Detection of denatured HBsAg using iirraunoblotting
Protein samples were electrophoresed at 4.5V/cm through a 13% (w/v) 
SDS-polyacrylamide gel (Laemmli, 1970) then irnmunoblotted on to 
nitrocellulose (Towbin et al.. 1979). Denatured HBsAg was detected 
by incubation with NPA/BC-4B anti-denatured yeast HBsAg serum, then 
goat anti-rabbit IgG Fc-alkaline phosphatase conjugate. Using 
transmission densitometry, the degree of staining was related to the 
amount of the 22kD form of HBsAg present using the positive control 
samples (P) (99% pure, pHIN/G-2 derived HBsAg of concentration 
0.6mg/ml), of which 40% was in the 22kD form, as standards. Lanes: 
PI - 12/zg 22kD HBsAg, P2 - 6/ig 22kD HBsAg, P3 - 2.4/ig 22kD HBsAg, P4 
- 1.8/jg 22kD HBsAg; 1-7 were ammonium sulphate fractions (20 - 35% 
saturation; 3.5mg protein) of DBY746 cell extracts, 1 - unmutated, 2
- 124cys- ser^ 3 _ pro -* giy
6 - 122arg ̂  lys , 7 - 134tyr " phe . Nl and N2 were ammonium sulphate 
fractions (20 - 35% saturation; 3.5mg protein) of extracts of DBY746 






































































estimated. The concentrations observed ranged from about 160ng to 
300ng HBsAg/mg total protein (0.56 to l.Sjug HBsAg/ml) .
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5. Kf.b'flCr OF MUTATIONS ON HBsAq IMMUNOREACITVITY
140
5. Effect of Mutations on HBsAa Immunoreactivity
5.1 Natations and d/v subtype
5.1.1 Assa for HBsAa subtype
The effect of mutations at IIS2^ ~* thr (adwl) , 122^ ~*Iys (adw2) ,
and 134 p (adw3) on the d/y subtype of HBsAg was determined 
using an assay which examined the reactivity of the protein with d 
and y monospecific antisera. A modification of a double antibody- 
radioiinrnunoprecipitation (DARIP) was used for the subtyping assay 
(Burrell et al. , 1978; section 2.2.4). The extent of inhibition of 
an anti-y or anti-d: [ 125I] -HBsAg (adw or ayw) reaction by test 
antigen was taken as an indication of the degree of avidity the 
antigen had for the monospecific antiserum (figure 5.1.1). The 
specificity of the assay was demonstrated using a series of standard 
HBsAg preparations of known subtype (figure 5.1. IB). The reactivity 
of HBsAg with a subset of anti-HBsAg antibodies was the original 
feature used in the definition of subtype (Le Bouvier et al . , 1971).
5.1.2 Effect of mutations on d/y subtype
The subtype of unmutated HBsAg produced from the S gene of pHIN/G-2 
(wt) was defined as y+d~ by competition DARIP (figure 5.1.2). The 
three single amino acid substitutions in HBsAg (adwl, adw2, adw3) had 
no detectable influence on the d/y subtype.
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Figure 5.1.1 Use of monospecific antisera to define the d/v
subtype of HBsAg
A. The relative avidity of test antigen for d or y monospecific 
antisera was indicated by the extent of inhibition of the 
reaction between monospecific antiserum and labelled HBsAg of 
subtype adw or avw. The complexes formed between antibody and 
antigen were precipitated by donkey anti-rabbit IgG serum; 
with the extent of reduction in label precipitated indicating 
the relative avidity of test antigen for monospecific 
antiserum.
B. Standard HBsAg preparations, of known subtype, were used to 
establish the specificity of the competition double antibody 
radioimmunoprecipitation assay (Burrell et al.. 1978). The 
reaction between monospecific anti-d or anti-y sera and 
labelled HBsAg of subtype adw or avw was inhibited in a subtype 




























































































































Figure 5.1.2 Effect of single amino acid substitutions on the d/v
subtype of HBsAg
The subtype of S. cerevisiae expressed HBsAg was defined by the 
degree of inhibition of anti-d: HBsAg adw or anti-y: HBsAg ayw 
reaction. The concentration of antigen was determined by the Abbott 
Ausria II radioimmunoassay for human HBsAg, calibrated with a 











































































































A combination of either mutation 122arg ~*lys or 134tyr ~* phe with 
113ser ""* resulted in a switch from a y+d~ to a y+d+ subtype 
(figure 5.1.3). The increase in d—reactivity was slightly more 
pronounced in adw2.1 HBsAg than adw3.1. The degree of y-antigenicity 
was detectably diminished by both double mutations. The effect of 
combining all three mutations was to slightly increase d-antigenicity 
and to further decrease y-antigenicity. These results indicate that 
the appearance of the d-subtype depends on the nature of the amino 
acids present at two positions. The complete switch from y to d can 
almost be achieved by the substitution of amino acids at three 
positions. However, the nature of the residue at one particular 
position, even if the residue at that position correlates exactly 
with a subtype (such as 122 , figure 1.4.2), had no detectable bearing 
on the d/y subtype of the antigen.
5.1.3 Effect of mutations on the binding of a d-specific monoclonal 
antibody
The specificity of the mouse monoclonal antibody 1E6 (a gift from 
The Green Cross Corporation, Osaka) was demonstrated using HBsAg of 
subtype adw and avw in a radioimmunoassay. The monoclonal antibody 
was immobilised on polyvinyl beads (60/ig/ml antibody in 012M NaHC03 
pH 9.2 for 16 hours at room temperature), and used with [ 125I]-anti- 
human HBsAg second antibody according to the Abbott Ausria II 
protocol.
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Figure 5.1.3 Effect of multiple amino acid substitutions on the
d/y subtype of HBsAg
The assay, controls and determination of concentration of HBsAg were 










































































































































The monoclonal antibody exhibited subtype specificity in the assay, 
reacting with the adw, but not the ayw. antigen (figure 5.1.4A). The 
unmutated antigen (wt) reacted with the d-specific monoclonal 
antibody to the same extent as a bona fide adw antigen. The three 
singly mutated HBsAg proteins, adwl, adw2, and adw3, also exhibited 
similar reactivity with the antibody. The multiply-mutated antigens 
(adw2.1, adwS.l, adw2.1.3) showed no significant deviation from the 
behaviour of the unmutated antigen to the d-specific monoclonal 
antibody.
These results indicate that HBsAg subtyped as a d" shows the same 
relative affinity to a d-specific monoclonal antibody as that of a d+ 
antigen. Mutations which bring about a d"1" subtype do not alter the 
reactivity of the antigen to the monoclonal antibody compared with 
that of d" antigen.
5.2 Subtype-Specificity of Antisera Raised Against Mutant HBsAq
Mutant and wild type (ayw) HBsAg was used to immunise Balb/c mice 
(section 2.2.4). The relative anti-HBsAg titres of the antisera 
produced were determined by observing relative avidity with [ 125I]- 
HBsAg in a DARIP assay (Burrell et al., 1978). Titres were expressed 
as the dilution capable of precipitating 50% of the maximum 
precipitable HBsAg (figure 5.2.1). The relative avidity of antisera 
for d and y determinants was indicated by the ability of the mouse 
sera to inhibit anti-d or anti-y: [ 125I]-HBsAg (adw or ayw) reactions.
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Figure 5.1.4 Effect of amino acid substitutions on the reactivity
of HBsAg to a d-specific monoclonal antibody
The reactivity of test antigen with the monoclonal antibody was 
assessed by radioimmunoassay. The relative amount of HBsAg bound to 
monoclonal antibody coated beads (in a standard volume) was expressed 
as the ratio: amount of [ 125I]-anti-HBsAg antibody bound to 
immobilised antigen (P) to the amount of [ 125I]-anti-HBsAg antibody 
associated with the negative control (RIP buffer) (N). The standard•
concentration of HBsAg used was determined as in figure 5.1.2. 
A. Effect of single adw mutations on reactivity. 
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Figure 5.2.1 Titre of anti-yeast HBsAg sera from Balb/c mice
Animals were inoculated once and boosted twice with pKEN/G-2 derived 
HBsAg from mutant DBY746 strains (adwl, adw2, adw3, adw2.1, adw3.1, 
adw2.1.3) and unmutated cells (wt). Cells not transformed with 
pHIN/G-2 were also used to make extracts which were used to produce 
mouse antiserum (N). The titre of anti-HBsAg antisera was indicated 
by the degree of precipitation of [ 125I]-HBsAg in a double antibody 
radioimmunoprecipitation assay, using sheep anti-mouse second 
antibody.
The titre of each antiserum was indicated by noting the dilution 
necessary to give 50% of the maximum level of precipitated antigen, 
which was 65% of total label. This precipitation level (32%) was 
used and the titres were: wt - 1/19, adwl - 1/94, adw2 - 1/178, adw3 
- 1/154, adw2.1 - 1/188, adw3.1 - 1/82, adw2.1.3 - 1/11. These 
titres were used to then normalise all future measurements taken on 






































































Test antiserum (mouse) complexes with antigen were not precipitated 
by the donkey anti-rabbit IgG second antiserum (figure 5.2.2) .
The antiserum raised against the unmutated HBsAg (wt) displayed the
specificity anti-y+anti-cT (figure 5.2.3). The effect of the
™ , 4-^.1- -i^,, inSer -»• tyr .-_arg -»• lys __.tyr -»• phe ., , , mutations 113 2 , 122 ^ J , 134 •* * on the subtype
specificity of the antisera was to induce the production of anti-d 
antibodies and reduce the avidity of anti-y antibodies. Mutation at 
residue 122 (arg -+ lys) had greater effect than the mutation at 113 
(ser -»• thr) and 134 (tyr -»• phe) on introducing d-avidity and 
decreasing y-avidity.
The antisera derived from the double (adw2.1, adw3.1) and triple 
mutants (adw2.1.3) revealed a greater relative avidity for d-antigen 
than the antisera derived from unmutated or singly mutated HBsAg 
(figure 5.2.4). All three antisera exhibited a marked decrease in 
anti-y avidity, with anti-adw 2.1.3 serum possessing no detectable 
anti-y avidity. The substitutions at 113, 122, and 134, if present 
in the same protein, are capable of redirecting the production of 
subtypic antisera from y to d. The amino acid position which had the 
greatest influence on d/v subtype immunogenicity was 122 (y - arg, d 
- lys) .
5.3 Mutations in the a-Region and HBsAg Antigenicity
^ 4. *.- i^ -> ser i/ioP10 ~" e IA^P^ "" 9y lA-?^3 ~" serThe mutations 124 2 , 142^ , 142 , 147 
in HBsAg were made to test the contribution of each of the residues
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Figure 5.2.2 Determination of the subtype specificity of anti-
HBsAg sera
The relative avidity of mouse test-antiserum for the d or y-epitopes 
present on labelled HBsAg was indicated by the degree of inhibition 
the serum exerted on the monospecific antiserum labelled HBsAg 
reaction. The d/y-specific sera were produced from rabbit anti-HBsAg 
sera so only complexes between these antibodies and HBsAg will be 
precipitated by the second antibody (donkey anti-rabbit IgG). 
Labelled HBsAg:mouse test-antibody complexes will not be precipitated 
and so will diminish the degree of label recovered in the 
precipitate. The relative level of the decrease in precipitation 
indicated the avidity of the test antiserum for d or y features of 
HBsAg.
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Figure 5.2.3 Effeet of single amino acid substitutions in HBsAg on
subtype specificity of anti-HBsAg antibodies
The assay for relative avidity of anti-HBsAg serum for d or y 
determinants was carried out using the assay described in figure 
5.2.2. The negative control antiserum (N - raised against extracts 
from untransformed DBY746 cells) when tested in the assay gave a 
level of about 45% precipitated [ 125I]-HBsAg over the relevant range 
of dilution. The reagents used in the assay (standard monospecific 
antisera, labelled antigen) were from batches previously tested for 
subtype specificity (figure 5.1.IB). The relative anti-HBsAg titre 
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Figure 5.2.4 Effect of multiple amino acid substitutions in HBsAg
on subtype specificity of anti-HBsAg antibodies
The assay, controls and relative anti-HBsAg titre of antisera were 


























in determining HBsAg antigenicity. The concentration of HBsAg 
present in preparations of DBY746 cell extracts was determined for 
the denatured form of the protein (section 4.2, figure 4.2.1). This 
estimation therefore gave an indication of the concentration of HBsAg 
irrespective of any antigenic property of the native protein, and 
allowed the determination of the effect of mutations in the a-region 
on a-antigenicity of HBsAg at standard concentrations.
5.3.1 Effect on a-antigenicitv of mutations in the a-region
Since the majority of antibodies present in an anti-HBsAg serum are 
directed against a-specific epitopes (McAuliffe et al., 1980), such 
an antiserum was used to estimate the relative antigenicity of a- 
regions in mutant and wild type HBsAg proteins. The Abbott Ausria 
II radioimmunoassay detection system for HBsAg was therefore used for 
this purpose.
Both amino acid substitutions at positions 142 (pro -» ile, pro -* gly) 
had a significant effect on a-antigenicity, reducing it compared with 
that of the unmutated antigen (figure 5.3.1). The isoleucine 
substitution had a greater effect than the glycine substitution. The 
cys -»• ser changes at positions 124 and 147 diminished antigenicity, 
with the 147 substitution all but abolishing a-antigenicity 
completely. The two subtype specific alterations (122^ ~" ys , 
134tvr ~* phe) although situated in the vicinity of the a-specific 
changes, did not significantly alter a-antigenicity, therefore
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Figure 5.3.1 Effect of mutations on a-antigenicity
The Abbott Ausria II radioimmunoassay for the detection of human 
HBsAg was employed to assess the a-antigenicity of wild type (wt) 
HBsAg and mutant HBsAg - 124 cys ~* ser (a3) , 142pro ~" gly (al) ,
142pro -* ile (a2) f 147cys -* ser (a4) ̂  ^arg -* lys (adw2) ̂  134tyr
(adw3) . The relative amount of HBsAg bound to polystyrene beads 
coated with anti-human HBsAg antibody (in a standard volume) was 
expressed as the ratio: amount of [ 125I]-anti-HBsAg bound to 
immobilised antigen (P) to the amount of [ 125I]-anti-HBsAg associated 
with the negative control (RIP buffer) (N) . The concentration of 


























































discounting the effects of non-specific amino acid changes on a- 
antigenicity.
5.3.2 Influence of the a-region on d/y subtype
To investigate whether or not a fully antigenic a-region is necessary 
for the presence of antigenic d/y regions, the mutants deficient in 
a-antigenicity were subjected to subtype analysis. The assay used 
was that described in section 5.1.1 (figure 5.1.1), being based on a 
competition double antibody-radioimmunoprecipitation procedure. All 
four mutants exhibiting impaired a-antigenicity (al - a4) showed 
substantial decreases in y-antigenicity compared with that of the 
unmutated antigen (figure 5.3.2). There was no change in d-
antigenicity from the negligible level observed for unmutated (wt)
cvs ~* ser antigen. As in the case of a-antigenicity, the mutation 147 *
had the greatest effect on y-antigenicity, completely abolishing any 
inhibition by the antigen of the anti-y: [ 125I]-HBsAg (aw) reaction. 
The mutations 122arg ~* lys and 134tyr ~* ^e which had no effect on a- 
antigenicity did not alter y or d-antigenicity. From these results 
it is clear that perturbation of a-region antigenicity leads to 
changes in the antigenicity of adjacent but immunologically distinct 
peptide regions.
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Figure 5.3.2 Effect of amino acid substitutions in the a-region on
the d/y subtype of HBsAg
The subtype of HBsAg was defined using the experiment described in 
























































































































































5.3.3 Effect of mutations in the a-region on the binding of a d- 
specific monoclonal antibody
The radioimmunoassay described in section 5.1.3, was used to compare 
the relative affinities of HBsAg proteins mutated at positions 124, 
142 and 147 and the wild type protein with the d-specific monoclonal 
antibody 1E6. All of the a-specific mutations identified in section 
5.3.1 reduced the affinity of HBsAg for the d-specific monoclonal 
antibody (figure 5.3.3). Ihis further indicates the importance of 
the iiranuTKDdominant a-region in determining the antigenicity of 
adjacent peptide regions which harbour immunologically separate 
epitopes.
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Figure 5.3.3 Effect of amino acid substitutions in the a-region on
HBsAg reactivity to a d-specific monoclonal antibody
Hie reactivity of HBsAg to the monoclonal antibody was assessed by 
radioiraraunoassay. The relative amount of HBsAg bound to polystyrene 
beads coated with monoclonal antibody (in a standard volume) was 
ejqpressed as the ratio: amount of [^^IJ-anti-HBsAg antibody bound 
to immobilised antigen (P) to the amount of [ 125I]-anti-HBsAg 
antibody associated with the negative control (RIP buffer) (N). The 

















This thesis has been concerned with an investigation into the factors 
responsible for determining the antigenicity and immunogenicity of a 
viral antigen. Since the serology of HBsAg is well defined and the 
location of antigenically important regions known, this protein 
provided an ideal system to study the amino acid residues involved in 
specific cross-reactions. The technique of oligonucleotide-mediated 
site-directed mutagenesis has been used to introduce specific 
nucleotide substitutions in the S gene of HBV. The gene was 
expressed in S. cerevisiae and gave rise to HBsAg harbouring 
predetermined mutations in the antigenic region.
To investigate the molecular basis of d/y subtype specificity, the 
effects of mutations at 113 (ser -* thr), 122 (arg -»• lys) and 134 (tyr 
-»• phe) on antigenic and djnmunogenic subtypic activity were assessed. 
The contributions of amino acids proline 142, cysteine 124 and 
cysteine 147 in determining the a-antigenicity of HBsAg were also 
investigated, using a similar mutational approach. The influence of 
the a-region on the antigenicity of adjacent peptide regions was also 
assessed.
6.1 Mutational Analysis of the d/y Subtype of HBsAg
A summary of the immunological properties of d/y mutant-HBsAg can be 































































































































































































































































































































































































































































































6.1.1 Distinction between the y_ and d antiaenic subtypes is not 
attributable to a single amino acid difference
An approach that has been used to define the molecular basis of HBsAg 
subtype specificity involves the identification of amino acid 
positions which correlate with the presence of a specific subtype. 
The result of this comparative method implicated amino acid positions 
68 and 122 in defining the d/y subtype (figure 1.4.2). Several 
groups of workers equipped with this information have focussed their 
attention on these residue positions. It has been established that 
differences in amino acid at position 122 determines the binding of d 
(lysine) and y (arginine) specific monoclonal antibodies (Peterson et 
al., 1984; Okamoto et al., 1986, 1987a). No group has investigated 
the contribution of residues at 68 on d/v subtype presumably since 
there is no evidence implicating the region around 68 in the 
participation of antigenic reactions (Prince et al., 1982; Bhatnager 
et al., 1982; Lsrner et al.. 1981; Gerin et al.. 1983).
However, it was found that the change at 122 from the y specific to 
the d specific amino acid did not alter subtype, as defined by the 
avidity of the antigen for monospecific, polyclonal anti-d or anti-y 
sera (figure 5.1.2). To account for the discrepancies between the 
two results, it is suggested that the anti-d and anti-y monoclonal 
antibodies which have been used previously to define subtype, do not 
faithfully represent the whole population of subtype specific 
antibodies present in anti-d and anti-y sera.
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6.1.2 The reaction of HBsAg with a subtype-specific monoclonal 
antibody does not define subtype
Unmutated HBsAg produced from pHIN/G-2 had a y+d~ subtype (figure 
5.1.2). However, the antigen reacted with a d-specific monoclonal 
antibody (1E6) to some extent as did adw HBsAg (figure 5.1.4A) . This 
result highlights the fact that the designation of HBsAg depends on 
the interaction of several epitopes with several paratopes (Swenson 
et al. . 1988) . Therefore, the d-specific monoclonal antibody used in 
these experiments did not accurately reflect the subtype of the 
antigen presumably because in a d specific polyclonal antiserum the 
antibody in question is present in low amounts or binds with low 
affinity. Furthermore, mutations in HBsAg that changed the subtype 
from d~y+ to d+y* (adw2.1, adw3.1, adw2.1.3) did not increase the 
affinity of the d-specific monoclonal antibody for the epitope 
present in HBsAg (figure 5.1.4B).
6.1.3 Substitution of three amino acids allows the partial switch 
from y_ to d antigenic subtype
The mutations 122arg ~* lys and 134tyr ~* phe when combined with 
~* thr produced a dramatic increase in the avidity of HBsAg for 
monospecific d-antiserum (figure 5.1.3). When all three mutations 
were present in HBsAg the avidity for monospecific y-antiserum was 
noticeably decreased, with the avidity for the d-antiserum similar to 
that of the double mutant. The d/y subtype is dependent on the 
presence or absence of several epitopes (Swenson et al . . 1988), thus
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amino acid substitutions that switch subtype must alter the 
structure of the region such that a set of epitopes are abolished and 
another set created. Therefore, both double mutants must have 
altered the structure of the antigen in such a way as to establish 
the presence of d-epitopes whilst preserving the existing y-epitopes. 
The three mutations present in adw2.1.3 facilitated the adoption of a 
d-specific structure, whilst at the same time diminished the y-nature 
of the area. This confrontational basis for HBsAg subtype differences 
is consistent with the general features of the antigen.
Synthetic peptides corresponding to residues 110 - 137 of HBsAg as 
predicted from the S gene nucleotide sequences of HBV DNA from ayw 
and adw were tested for their ability to bind anti-ayw and anti-adw 
sera (Gerin et al.. 1983). It was found that the peptides exhibited 
subtype specificity in reactions with the sera, thus implicating the 
positions of amino acid variability (110, 114, 122, 125, 127, 131, 
134) in determining subtype specificity. Of the seven positions 
implicated by this study, substitutions at two (122, 134) have been 
shown sufficient to elicit the change y+d" to y+dT1" in the 
antigenicity of HBsAg when combined with the mutation 113ser ~* 
The contribution of 113 in d/y subtype was unexpected; the mutation 
at the position was made to serve as a negative control to the 
substitutions at 122 and 134, since variability at 113 is in 
accordance with w/r specificity. The most likely explanation is that
the mutation 113ser ~* ^^ was sufficiently similar to the y -* d
CZQV —* thr specific change 114 (Gerin et al., 1983) to allow it to
influence d/y antigenic behaviour.
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6.1.4 Amino acid residues at three positions define the immunoaenic 
d/y subtype of HBsAg
The single amino acid substitutions that had little effect on the d/v 
subtype of HBsAg resulted in substantial changes in the subtype 
specificity of anti-HBsAg sera (figure 5.2.3). Ihe contribution of 
residues at 114, 122 and 134 in determining the immunogenic as well 
as the antigenic subtype of HBsAg has been reported (Gerin et al. , 
1983) in the case of peptides representing a region 110 - 139 of 
HBsAg.
The mutation at 122 had a more pronounced effect than the 134 or 113 
mutations, when singly present or with 113 the mutation at (figure 
5.2.4). This result would have been predicted from studies 
correlating the position of variable amino acid residues with subtype 
(figure 1.4.2), since residues at 122 correlate exactly with the 
appearance of the d/y subtype. Ihe residues present at 122 (y - arg, 
d - lys) are likely to be immunogenic to B-cells and located at the 
surface of the antigen since they possess positively charged, 
hydrophilic side groups (Hopp and Woods, 1981). Residues at 122 
would therefore participate to a large degree in determining the 
antigenic and immunogenic behaviour of HBsAg.
The three mutations present in adw2.1.3 changed the specificity of 
anti-HBsAg sera from y to d. The possibility that other areas of 
HBsAg contribute to the determination of the subtype specificity
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still remains, however this study has identified the minimum 
structural changes necessary for the specificity switch.
The changes observed in the subtype of anti-HBsAg sera due to 
substitutions of amino acids at positions 113, 122 and 134 were more 
pronounced than changes observed in the subtype antigenicity of HBsAg 
protein. Furthermore the dominant effect of position 122 on subtype 
reactivity was best detected by the observation of changes in HBsAg 
immunogenicity rather than antigenicity. Ihis greater influence of 
mutations on HBsAg iinmunoreactivity can be best explained by assuming 
that the in vivo detection of alterations in immunogen structure, 
afforded by the immune system of Balb/c mice, exhibited greater 
sensitivity than the in vitro reaction used to detect changes in 
antigenicity.
The contribution of T-cell specific epitopes to the iinmune response 
against HBsAg is well established (Roberts et al.. 1975). A region 
(24 - 27) of HBsAg has been shown to be capable of inducing T-helper 
cell proliferation (Celis et al.. 1988), however no amino acid 
variation occurs in this region, so it is unlikely that it 
contributes to iinmunogenic subtype differences. Like other viruses, 
HBV triggers the cell-mediated and humoral immune systems, a 
consequence being the priming of anti-HBsAg antibody production by 
activated T-cells specific for other viral immunogens (Vento et al., 
1987; Milich et al., 1987a, b, c, 1988). Such an arrangement could 
determine the subtype specificity of anti-HBsAg sera through
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variation in T-cell epitopes located in virion components other than 
HBsAg.
6.2 The a-Reaion of HBsAa
6.2.1 Mutations and a-antiaenicitv
The effects of the amino acid substitutions at positions 124 (cys -»• 
ser), 142 (pro -+ gly, pro -»• ile) and 147 (cys -»• ser) on HBsAg a- 
antigenicity are summarised in table 6.2. The residues at these 
positions, cysteine or proline, play an important role in the 
determination of polypeptide conformation in proteins. The cysteine 
residues will in all likelihood be involved in stabilisation through 
disulphide bridges, and the proline would also be conformationally 
significant, dictating a turn in the polypeptide chain. Substitution 
of the proline with isoleucine decreases antigenicity more than 
substitution with glycine (figure 5.3.1), which is consistent with 
the above postulate; the bulky hydrophobia isoleucine side chain may 
impede the turn more than the glycine which allows relatively free 
movement of the peptide (Gamier et al., 1978).
It has been shown that the cysteines at positions 124 and 147 are 
both required for full a-antigenicity, but that at 147 is virtually 
indispensible, suggesting that this residue participates in a 
disulphide bridge that is essential for maintenance of the correct 
arrangement of the antigen. The role of cysteines in maintaining 


















































































































































































































(Dreesman et al., 1987; Sukeno et al. f 1972; Vyas et al., 1972). 
Studies with synthetic peptides identified the regions between 
residues 122 and 137 (Dreesman et al.. 1982) and residues 139 and 147 
(Brown et al. , 1984) as contributors to a-antigenicity and shows 
further that cyclisation through cysteine residues 124 and 137 or 139 
and 147, as indicated in figure 1.5.2, enhanced a-immunoreactivity. 
Together these experiments support the view that cystine bridges 
involving residues 124 and 147 with one of the cluster of cysteines 
at 137 and 139 have a direct role in determining the conformational 
integrity of the a-antigenic region. It is interesting to note in 
contrast that substitution of cysteine 121 to serine had little 
effect upon reactivity of the antigen with its antibody in the 
"Ausria" radioimmunoassay, whereas against a panel of five monoclonal 
antibodies specific for the a-region reactivity was greatly reduced 
or eliminated in three and enhanced in two (Antoni and Peterson, 
1988).
The production of further HBsAg proteins which have undergone 
substitution of cysteines for serines in the a-region will allow the 
further investigation of the contribution of cystine bridges in 
maintaining HBsAg antigenicity.
Experiments with synthetic peptides have been used in studies of 
subtype specificity and have implicated amino acid residues at 122 
and 134 in the determination of the d/y subtype specificity, but not 
a-antigenicity (Gerin et al., 1983). These residues therefore 
provided a reference against which to assess the effect of other
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alterations in local peptide structure on a-antigenicity. That 
these substitutions at these positions did not affect a-antigenicity 
reinforces the view that the changes observed with the four mutants 
at positions 124, 142 and 147 were attributable to significant 
deformations of the native structure of HBsAg.
6.2.2 Influence of a-reaion on d/y subtype
Mutations that diminished a-antigenicity also affected the extent of 
d/y antigenicity (figure 5.3.2). Furthermore, the affinity of HBsAg 
for a d-specific monoclonal antibody was reduced (figure 5.3.3). 
These results imply that the antigenic integrity of the immuno- 
dominant a-region (residues 138 - 147) is necessary for the optimal 
antigenic expression of the subtype determining regions of the 
protein. Any loss of integrity of the a-region would be likely to 
result in a change of conformation of adjacent epitcpes not normally 
recognised by a-specific antibodies. This would probably drastically 
affect the antigenicity of non-cross reacting epitopes such as those 
which are subtype specific.
6.3 T.imitations of the Thesis
The effects of each mutation made in HBsAg were assessed at the level 
of immunoreactivity, such that changes in the prijmary structure of 
the protein were related to a change in a biological property. As 
stated throughout the thesis, the B-cell immunoreactivity of protein 
antigens is largely dictated by the spatial arrangement of
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constitutive polypeptides. However, in the study described no means 
to assess alteration in antigen conformation were employed. Any 
change in immunoreactivity observed gave rise to the proposal of 
hypothetical changes in conformation. The indirect nature of the 
approach used in the study described is shared by other methods 
employed to investigate B-cell-specific antigenic structure, such as 
experiments involving the use of synthetic peptides.
The use of X-ray diffraction-crystallography to investigate protein 
structure allows a comprehensive analysis of epitope structure; such 
that any changes in immunoreactivity can be directly rationalised in 
terms of altered protein conformation.
Another limitation of the study, and of all similar studies, is the 
extent of the mutational analysis conducted. In the case of the 
investigation of a-antigenicity, the residues chosen for mutagenesis 
were four out of several other residues of similar apparent 
importance in maintaining conformation. For example, the extent of 
mutational analysis could be increased to include other proline and 
cysteine residues present in the vicinity. Such work is in progress, 
and the results are eagerly awaited.
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APPENDIX A 
Nucleotide sequence of the HBV genome
Shown is the DNA sequence of the HBV genome (subtype avw) as cloned 
by Pasek et al. (1979), 3182 nucleotides long. The numbering of 
nucleotides is based on the start of the core gene being 1. Below 
the gene sequences are the corresponding translation products in all 
three phases (a, b, c) . The starts of HBV ORFs map to the following 
positions: Core - la, polymerase - 407b, pre Surface 1 - 948c, pre 
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Nucleotide sequence of the S gene
Shown is the DNA sequence (1437 - 2114) of the S gene of HBV, as 
cloned by Pasek et al. (1979), subtype ayw. The numbering of 
nucleotides is as in Appendix A. Below the nucleotide sequence is 












1557 ——> ———————*—————————————————————————————————————— 1616 
Ph«L«uGlyGlyThrThrVaiCysL«uGlyGlnAsnS«rGlnS«cProIleS«rAsnflis
1630 1650 1670 
TCACCAACCTCCTGTCCTCCAACTTGTCCKXSTTATCGCTGGATGTGTCTGCGGCG
1617 ——*————————-f———————+—r————-*———————-*———————-»•————— 1676 
S«cProThrS«rCysProProThrCysProGlyTyrArgTrp««tCysLeuArgArgPhe
1690 1710 1730 
ATCATCTTCCIXrrTCATCCTGCTGCTATGCt?TCATCrrCTTC




1737 ——+———————+———————»———————*———————f———————*———— 1796 
GlnGlyM«tL«uProValCysProL«uIleProGlyS«rSerThrThrS«rThrGlyPro




1870 1890 1910 











1977 —— * ——————— * ——————— * ——————— * ——————— * ——————— > ———— 203< 
GlnTrpPh«V*lGlyL«uS«rProIl«ValTrpL«u««r9alIl«trpM«tM«tTrpTyr
2050 2070 2090 
fyfr^<^t>r\^f\fff I-KZJLCTTJv i f n- f arrcrrcTTArrJLt i p f M- > P r
2037 ——»———————*———————*———————'———————>———————*————
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Antiaenic Index: This feature indicated the probability that a 
region be antigenic based on a summation of several, weighted, 
measures of secondary structure, such as flexibility, hydrophilicity 
and surface probability. The method used was that of Jameson and 
Wolf (CABIOS in press).
The methods of Chou and Fasman (CF) (1978) and Gamier, Osguthorpe 
and Robson (GOR) (1978) were used to predict helices, ^-sheets and 
peptides turns.
Glycosylation sites: These were predicted for sites where the 
residues have the composition N X T or N X S, when X is D, W or P the 
site is taken to be a weak glycosylation site, otherwise it is taken 
as a strong glycosylation site, i.e. highly probable.
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APPENDIX C
Biophysical secondary structure prediction for the S gene product of
HBV
Using the peptide sequence of HBsAg, deduced from the nucleotide 
sequence of the S gene (Pasek et al., 1979; Appendix B), predictions 
of secondary structure were undertaken.
The UWGCG peptide structure program was used to perform the following 
predictions:
HW Hydrophilicitv; The Hopp and Woods (1981) method for assessing 
local hydrophilicity of peptide regions was used. The window was set 
to 7 residues for this study.
Log Surface Probability: Using the method described by Emini et al. 
(1985) the probability of a short peptide region appearing on the 
hydrophilic surface of a protein was determined. Each amino acid is 
assigned a value relating to the degree of likelihood of it 
appearing at the surface of the molecule. These values are combined 
in the method to give an overall propensity of surface appearance for 
the molecule.
Flexibility: The predicted ease of movement about the alpha-carbon 























Hamology based secondary structure prediction for the S gene product 
of HBV
The peptide sequence of HBsAg, deduced from the nucleotide sequence 
of the S gene cloned by Pasek et al. (1979) (Appendix B) was used in 
the method of Coulson et al. (1987) to predict the secondary 
structure of HBsAg.
The peptide sequence was compared with a database of protein 
sequences of known crystal structure; for every point of homology 
recorded, the relevant secondary structure present at that point was 
recorded. E - /3-sheet, H - a-helix, T - turn.
An amino acid with no corresponding prediction showed no homology to
any of the sequences stored in the database.
1 MENITSGFD3 PLLVI£AGFF IITOIKCTPQ SIDSWWTSLN RLGGTTVCD3
EEEEEHT T EEEEETHHHH EE KFK E EE H:KH:K HHHHEEEEEE 
51 QNSQSPISNH SPTSCPPTCP GYRWMCISRF IIFLFTLLD3 IJFLLVLIJDY
KKKKKKKKhiK EEEEETT T TEEEEHHHHH EEEEHHEEEH HHHEEEEEEE 
101 GMLPVCPLI PSGGTTSTGP O3TCITPAQG ISMYPSCCCT KRSDGNCTCI
EE KKKKh?i-rFRF: HHEETEEEEE liTJibT KKH:H:
151 PIPSSWAFGK FIMEWASAPxF SWLSULVPFV QWFVGLSPIV WI5VTWMMWY 
FRE KKKKKK' HHHHHHHHHE EEEEEEEHHH HHHEEEEEEE EE KhhiKKttK 
201 WGPSLYSIIS PFLPIIPIFF CLWAYI
HHHHHH
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